{
    "abstract": "Continuing investments in vaccine innovation are insufficiently translated into market entries of novel vaccines. This innovation paradox is in part caused by stakeholders lacking complete understanding of the complex array of steps necessary for vaccine development and collaboration difficulties between the wide variety of stakeholders involved. Models providing cross-domain understanding can improve collaboration but currently lack both comprehensibility and granularity to enable a prioritized view of activities and criteria. Key opinion leaders (KOLs) were asked to contribute to the definition of a vaccine innovation cycle (VIC). In a first step, 18 KOLs were interviewed on the stages (activities and results) and gates (evaluation criteria and outcomes) of vaccine innovation. This first description of the VIC was subsequently validated and refined through a survey among 46 additional KOLs. The VIC identifies 29 distinct stages and 28 corresponding gates, distributed in ten different but integrated workstreams, and comprehensibly depicted in a circular innovation model. Some stage-gates occur at defined moments, whereas the occurrence and timing of other stage-gates is contingent on a variety of contextual factors. Yet other stage-gates continuously monitor internal and external developments. A gap-overlap analysis of stage-gate criteria demonstrated that 5 out of 11 criteria employed by vaccine developers correspond with criteria employed by competent (regulatory) authorities. The VIC provides a comprehensive overview of stage-gates throughout the value chain of vaccine innovation. Its cyclical nature highlights the importance of synchronizing with unmet needs and market changes, and conceptualizes the difference between incremental and radical vaccine innovation. Knowledge on the gap between internal and external criteria will enhance the viability of newcomers to the field. The VIC can be used by stakeholders to improve understanding and communication in forming collaborative alliances and consortia. Such a boundary-spanning function may contribute to the reduction of process inefficiencies, especially in public-private partnerships.",
    "author_highlights": [
        {
            "endOffset": 33347,
            "sentence": "The full vaccine innovation cycle is described by 29 distinct stages and 28 corresponding gates.",
            "startOffset": 33251
        },
        {
            "endOffset": 33436,
            "sentence": "A cyclical innovation model highlights the importance of synchronizing with unmet needs.",
            "startOffset": 33348
        },
        {
            "endOffset": 33516,
            "sentence": "Internal criteria for continued development are broader than external criteria.",
            "startOffset": 33437
        },
        {
            "endOffset": 33609,
            "sentence": "An overarching conceptual model for vaccine innovation may reduce innovation inefficiencies.",
            "startOffset": 33517
        }
    ],
    "bib_entries": {
        "b0005": {
            "authors": [
                {
                    "first": "David E.",
                    "initial": "D.E.",
                    "last": "Bloom"
                }
            ],
            "doi": "10.1007/978-1-4419-7185-2_1",
            "firstpage": "1",
            "issn": "00652598",
            "lastpage": "8",
            "pmid": "21120715",
            "pub_year": 2011,
            "title": "The value of vaccination",
            "volume": "697"
        },
        "b0010": {
            "authors": [
                {
                    "first": "Jagannath M.",
                    "initial": "J.M.",
                    "last": "Muzumdar"
                },
                {
                    "first": "Richard R.",
                    "initial": "R.R.",
                    "last": "Cline"
                }
            ],
            "doi": "10.1331/JAPhA.2009.09007",
            "firstpage": "e87",
            "issn": "15443191",
            "lastpage": "e99",
            "pmid": "19589753",
            "pub_year": 2009,
            "title": "Vaccine supply, demand, and policy: A primer",
            "volume": "49"
        },
        "b0015": {
            "authors": [
                {
                    "first": "Heini",
                    "initial": "H.",
                    "last": "Salo"
                },
                {
                    "first": "Terhi",
                    "initial": "T.",
                    "last": "Kilpi"
                },
                {
                    "first": "Harri",
                    "initial": "H.",
                    "last": "Sintonen"
                },
                {
                    "first": "Miika",
                    "initial": "M.",
                    "last": "Linna"
                },
                {
                    "first": "Ville",
                    "initial": "V.",
                    "last": "Peltola"
                },
                {
                    "first": "Terho",
                    "initial": "T.",
                    "last": "Heikkinen"
                }
            ],
            "doi": "10.1016/j.vaccine.2006.03.057",
            "firstpage": "4934",
            "issn": "0264410X",
            "lastpage": "4941",
            "pmid": "16678945",
            "pub_year": 2006,
            "title": "Cost-effectiveness of influenza vaccination of healthy children",
            "volume": "24"
        },
        "b0020": {
            "authors": [
                {
                    "first": "Fangjun",
                    "initial": "F.",
                    "last": "Zhou"
                },
                {
                    "first": "Jeanne",
                    "initial": "J.",
                    "last": "Santoli"
                },
                {
                    "first": "Mark L.",
                    "initial": "M.L.",
                    "last": "Messonnier"
                },
                {
                    "first": "Hussain R.",
                    "initial": "H.R.",
                    "last": "Yusuf"
                },
                {
                    "first": "Abigail",
                    "initial": "A.",
                    "last": "Shefer"
                },
                {
                    "first": "Susan Y.",
                    "initial": "S.Y.",
                    "last": "Chu"
                },
                {
                    "first": "Lance",
                    "initial": "L.",
                    "last": "Rodewald"
                },
                {
                    "first": "Rafael",
                    "initial": "R.",
                    "last": "Harpaz"
                }
            ],
            "doi": "10.1001/archpedi.159.12.1136",
            "firstpage": "1136",
            "issn": "10724710",
            "lastpage": "1144",
            "pmid": "16330737",
            "pub_year": 2005,
            "title": "Economic evaluation of the 7-vaccine routine childhood immunization schedule in the United States, 2001",
            "volume": "159"
        },
        "b0025": {
            "authors": [
                {
                    "first": "Allan",
                    "initial": "A.",
                    "last": "Saul"
                },
                {
                    "first": "Katherine L.",
                    "initial": "K.L.",
                    "last": "O'Brien"
                }
            ],
            "doi": "10.1016/j.vaccine.2016.10.087",
            "firstpage": "A16",
            "issn": "0264410X",
            "lastpage": "A19",
            "pmid": "28017442",
            "pub_year": 2017,
            "title": "Prioritizing vaccines for developing world diseases",
            "volume": "35"
        },
        "b0030": null,
        "b0035": null,
        "b0040": {
            "authors": [
                {
                    "first": "Luigi",
                    "initial": "L.",
                    "last": "Orsenigo"
                },
                {
                    "first": "Giovanni",
                    "initial": "G.",
                    "last": "Dosi"
                },
                {
                    "first": "Mariana",
                    "initial": "M.",
                    "last": "Mazzucato"
                }
            ],
            "doi": "10.1017/CBO9780511493232.014",
            "firstpage": "402",
            "lastpage": "431",
            "pub_year": 2006,
            "title": "The dynamics of knowledge accumulation, regulation, and appropriability in the pharmabiotech sector: Policy issues"
        },
        "b0045": null,
        "b0050": null,
        "b0055": null,
        "b0060": {
            "authors": [
                {
                    "first": "Richard",
                    "initial": "R.",
                    "last": "Jefferson"
                }
            ],
            "doi": "10.1038/548S8a",
            "firstpage": "S8",
            "issn": "00280836",
            "pmid": "28792924",
            "pub_year": 2017,
            "title": "Comment: Turning science into social outcomes",
            "volume": "548"
        },
        "b0065": {
            "authors": [
                {
                    "first": "Jacqueline",
                    "initial": "J.",
                    "last": "Satchell"
                },
                {
                    "first": "Amanda",
                    "initial": "A.",
                    "last": "Stark"
                }
            ],
            "doi": "10.4155/fmc.11.70",
            "firstpage": "1089",
            "issn": "17568919",
            "lastpage": "1092",
            "pmid": "21806371",
            "pub_year": 2011,
            "title": "Experimental evidence to support a patent application: Are in silico data enough?",
            "volume": "3"
        },
        "b0070": null,
        "b0075": {
            "authors": [
                {
                    "first": "Drusilla L.",
                    "initial": "D.L.",
                    "last": "Burns"
                }
            ],
            "doi": "10.1016/j.coviro.2012.01.004",
            "firstpage": "353",
            "issn": "18796257",
            "lastpage": "356",
            "pmid": "22709520",
            "pub_year": 2012,
            "title": "Licensure of vaccines using the animal rule",
            "volume": "2"
        },
        "b0080": null,
        "b0085": null,
        "b0090": {
            "authors": [
                {
                    "first": "E. S.",
                    "initial": "E.S.",
                    "last": "Pronker"
                },
                {
                    "first": "T. C.",
                    "initial": "T.C.",
                    "last": "Weenen"
                },
                {
                    "first": "H. R.",
                    "initial": "H.R.",
                    "last": "Commandeur"
                },
                {
                    "first": "A. D.M.E.",
                    "initial": "A.D.M.E.",
                    "last": "Osterhaus"
                },
                {
                    "first": "H. J.H.M.",
                    "initial": "H.J.H.M.",
                    "last": "Claassen"
                }
            ],
            "doi": "10.1016/j.vaccine.2011.06.051",
            "firstpage": "5846",
            "issn": "0264410X",
            "lastpage": "5849",
            "pmid": "21722688",
            "pub_year": 2011,
            "title": "The gold industry standard for risk and cost of drug and vaccine development revisited",
            "volume": "29"
        },
        "b0095": {
            "authors": [
                {
                    "first": "Esther S.",
                    "initial": "E.S.",
                    "last": "Pronker"
                },
                {
                    "first": "Tamar C.",
                    "initial": "T.C.",
                    "last": "Weenen"
                },
                {
                    "first": "Harry",
                    "initial": "H.",
                    "last": "Commandeur"
                },
                {
                    "first": "Eric H.J.H.M.",
                    "initial": "E.H.J.H.M.",
                    "last": "Claassen"
                },
                {
                    "first": "Albertus D.M.E.",
                    "initial": "A.D.M.E.",
                    "last": "Osterhaus"
                }
            ],
            "doi": "10.1371/journal.pone.0057755",
            "issn": "19326203",
            "pmid": "23526951",
            "pub_year": 2013,
            "title": "Risk in Vaccine Research and Development Quantified",
            "volume": "8"
        },
        "b0100": {
            "authors": [
                {
                    "first": "Jeffrey",
                    "initial": "J.",
                    "last": "Almond"
                },
                {
                    "first": "Donata",
                    "initial": "D.",
                    "last": "Medaglini"
                }
            ],
            "doi": "10.1016/j.vaccine.2016.10.084",
            "firstpage": "A24",
            "issn": "0264410X",
            "lastpage": "A28",
            "pmid": "28017440",
            "pub_year": 2017,
            "title": "The role of the vaccines industry in Mission Grand Convergence",
            "volume": "35"
        },
        "b0105": {
            "authors": [
                {
                    "first": "Donata",
                    "initial": "D.",
                    "last": "Medaglini"
                },
                {
                    "first": "Magdalena R.",
                    "initial": "M.R.",
                    "last": "De Azero"
                },
                {
                    "first": "Odile",
                    "initial": "O.",
                    "last": "Leroy"
                },
                {
                    "first": "Florence",
                    "initial": "F.",
                    "last": "Bietrix"
                },
                {
                    "first": "Philippe",
                    "initial": "P.",
                    "last": "Denoel"
                }
            ],
            "doi": "10.1016/j.vaccine.2017.11.069",
            "firstpage": "1136",
            "issn": "0264410X",
            "lastpage": "1145",
            "pmid": "29395517",
            "pub_year": 2018,
            "title": "Innovation Partnership for a Roadmap on Vaccines in Europe (IPROVE): A vision for the vaccines of tomorrow",
            "volume": "36"
        },
        "b0110": {
            "authors": [
                {
                    "first": "Laura J.",
                    "initial": "L.J.",
                    "last": "Frost"
                },
                {
                    "first": "Michael R.",
                    "initial": "M.R.",
                    "last": "Reich"
                }
            ],
            "doi": "10.1377/hlthaff.28.4.962",
            "firstpage": "962",
            "issn": "02782715",
            "lastpage": "973",
            "pmid": "19597194",
            "pub_year": 2009,
            "title": "Creating access to health technologies in poor countries",
            "volume": "28"
        },
        "b0115": {
            "authors": [
                {
                    "first": "I.",
                    "initial": "I.",
                    "last": "Kola"
                }
            ],
            "doi": "10.1038/sj.clpt.6100479",
            "firstpage": "227",
            "issn": "00099236",
            "lastpage": "230",
            "pmid": "18202690",
            "pub_year": 2008,
            "title": "The state of innovation in drug development",
            "volume": "83"
        },
        "b0120": {
            "authors": [
                {
                    "first": "Rino",
                    "initial": "R.",
                    "last": "Rappuoli"
                },
                {
                    "first": "Donata",
                    "initial": "D.",
                    "last": "Medaglini"
                }
            ],
            "doi": "10.1126/scitranslmed.3003826",
            "issn": "19466234",
            "pmid": "22491948",
            "pub_year": 2012,
            "title": "ADITEC: Joining forces for next-generation vaccines",
            "volume": "4"
        },
        "b0125": {
            "authors": [
                {
                    "first": "Ashley J.",
                    "initial": "A.J.",
                    "last": "Birkett"
                }
            ],
            "doi": "10.1016/j.vaccine.2015.09.111",
            "firstpage": "7538",
            "issn": "0264410X",
            "lastpage": "7543",
            "pmid": "26469721",
            "pub_year": 2015,
            "title": "Building an effective malaria vaccine pipeline to address global needs",
            "volume": "33"
        },
        "b0130": {
            "authors": [
                {
                    "first": "Irina",
                    "initial": "I.",
                    "last": "Serdobova"
                },
                {
                    "first": "Marie Paule",
                    "initial": "M.P.",
                    "last": "Kieny"
                }
            ],
            "doi": "10.2105/AJPH.2005.074583",
            "firstpage": "1554",
            "issn": "00900036",
            "lastpage": "1559",
            "pmid": "16873743",
            "pub_year": 2006,
            "title": "Assembling a global vaccine development pipeline for infectious diseases in the developing world",
            "volume": "96"
        },
        "b0135": {
            "authors": [
                {
                    "first": "Rino",
                    "initial": "R.",
                    "last": "Rappuoli"
                },
                {
                    "first": "Donata",
                    "initial": "D.",
                    "last": "Medaglini"
                }
            ],
            "doi": "10.1016/j.vaccine.2014.06.071",
            "firstpage": "4705",
            "issn": "0264410X",
            "lastpage": "4707",
            "pmid": "24975815",
            "pub_year": 2014,
            "title": "Big science for vaccine development",
            "volume": "32"
        },
        "b0140": {
            "authors": [
                {
                    "first": "L. A.",
                    "initial": "L.A.",
                    "last": "Reperant"
                },
                {
                    "first": "L. H.M.",
                    "initial": "L.H.M.",
                    "last": "Van De Burgwal"
                },
                {
                    "first": "E.",
                    "initial": "E.",
                    "last": "Claassen"
                },
                {
                    "first": "A. D.M.E.",
                    "initial": "A.D.M.E.",
                    "last": "Osterhaus"
                }
            ],
            "doi": "10.1126/science.346.6208.433-b",
            "firstpage": "433",
            "issn": "00368075",
            "lastpage": "434",
            "pmid": "25342793",
            "pub_year": 2014,
            "title": "Ebola: Public-private partnerships",
            "volume": "346"
        },
        "b0145": null,
        "b0150": {
            "authors": [
                {
                    "first": "Stanley",
                    "initial": "S.",
                    "last": "Plotkin"
                },
                {
                    "first": "James M.",
                    "initial": "J.M.",
                    "last": "Robinson"
                },
                {
                    "first": "Gerard",
                    "initial": "G.",
                    "last": "Cunningham"
                },
                {
                    "first": "Robyn",
                    "initial": "R.",
                    "last": "Iqbal"
                },
                {
                    "first": "Shannon",
                    "initial": "S.",
                    "last": "Larsen"
                }
            ],
            "doi": "10.1016/j.vaccine.2017.06.003",
            "firstpage": "4064",
            "issn": "0264410X",
            "lastpage": "4071",
            "pmid": "28647170",
            "pub_year": 2017,
            "title": "The complexity and cost of vaccine manufacturing \u2013 An overview",
            "volume": "35"
        },
        "b0155": {
            "authors": [
                {
                    "first": "Einar",
                    "initial": "E.",
                    "last": "Rasmussen"
                }
            ],
            "doi": "10.1177/0266242610385395",
            "firstpage": "448",
            "issn": "02662426",
            "lastpage": "471",
            "pub_year": 2011,
            "title": "Understanding academic entrepreneurship: Exploring the emergence of university spin-off ventures using process theories",
            "volume": "29"
        },
        "b0160": {
            "authors": [
                {
                    "first": "Vathsala I.",
                    "initial": "V.I.",
                    "last": "Stone"
                },
                {
                    "first": "Joseph P.",
                    "initial": "J.P.",
                    "last": "Lane"
                }
            ],
            "doi": "10.1186/1748-5908-7-44",
            "issn": "17485908",
            "pmid": "22591638",
            "pub_year": 2012,
            "title": "Modeling technology innovation: How science, engineering, and industry methods can combine to generate beneficial socioeconomic impacts",
            "volume": "7"
        },
        "b0165": {
            "authors": [
                {
                    "first": "Barry C.",
                    "initial": "B.C.",
                    "last": "Buckland"
                }
            ],
            "doi": "10.1038/nm1218",
            "firstpage": "S16",
            "issn": "10788956",
            "pmid": "15812483",
            "pub_year": 2005,
            "title": "The process development challenge for a new vaccine",
            "volume": "11"
        },
        "b0170": {
            "authors": [
                {
                    "first": "John A.",
                    "initial": "J.A.",
                    "last": "Wagner"
                },
                {
                    "first": "Andrew M.",
                    "initial": "A.M.",
                    "last": "Dahlem"
                },
                {
                    "first": "Lynn D.",
                    "initial": "L.D.",
                    "last": "Hudson"
                },
                {
                    "first": "Sharon F.",
                    "initial": "S.F.",
                    "last": "Terry"
                },
                {
                    "first": "Russ B.",
                    "initial": "R.B.",
                    "last": "Altman"
                },
                {
                    "first": "C. Taylor",
                    "initial": "C.T.",
                    "last": "Gilliland"
                },
                {
                    "first": "Christopher",
                    "initial": "C.",
                    "last": "DeFeo"
                },
                {
                    "first": "Christopher P.",
                    "initial": "C.P.",
                    "last": "Austin"
                }
            ],
            "doi": "10.1111/cts.12531",
            "firstpage": "166",
            "issn": "17528054",
            "lastpage": "174",
            "pmid": "29271559",
            "pub_year": 2018,
            "title": "Application of a Dynamic Map for Learning, Communicating, Navigating, and Improving Therapeutic Development",
            "volume": "11"
        },
        "b0175": {
            "authors": [
                {
                    "first": "Caroline",
                    "initial": "C.",
                    "last": "Hussler"
                },
                {
                    "first": "Fabienne",
                    "initial": "F.",
                    "last": "Picard"
                },
                {
                    "first": "Ming Feng",
                    "initial": "M.F.",
                    "last": "Tang"
                }
            ],
            "doi": "10.1016/j.technovation.2010.06.003",
            "firstpage": "508",
            "issn": "01664972",
            "lastpage": "518",
            "pub_year": 2010,
            "title": "Taking the ivory from the tower to coat the economic world: Regional strategies to make science useful",
            "volume": "30"
        },
        "b0180": {
            "authors": [
                {
                    "first": "Loet",
                    "initial": "L.",
                    "last": "Leydesdorff"
                }
            ],
            "firstpage": "365",
            "issn": "00664200",
            "lastpage": "417",
            "pub_year": 2010,
            "title": "The knowledge-based economy and the triple helix model",
            "volume": "44"
        },
        "b0185": null,
        "b0190": {
            "authors": [
                {
                    "first": "Farah",
                    "initial": "F.",
                    "last": "Huzair"
                },
                {
                    "first": "Steve",
                    "initial": "S.",
                    "last": "Sturdy"
                }
            ],
            "doi": "10.1016/j.shpsc.2017.05.004",
            "firstpage": "11",
            "issn": "13698486",
            "lastpage": "21",
            "pmid": "28511068",
            "pub_year": 2017,
            "title": "Biotechnology and the transformation of vaccine innovation: The case of the hepatitis B vaccines 1968\u20132000",
            "volume": "64"
        },
        "b0195": {
            "authors": [
                {
                    "first": "Line",
                    "initial": "L.",
                    "last": "Matthiessen"
                },
                {
                    "first": "Hannu",
                    "initial": "H.",
                    "last": "L\u00e5ng"
                },
                {
                    "first": "Maria",
                    "initial": "M.",
                    "last": "Klimathianaki"
                },
                {
                    "first": "Finnian",
                    "initial": "F.",
                    "last": "Hanrahan"
                },
                {
                    "first": "Barbara",
                    "initial": "B.",
                    "last": "Kersti\u00ebns"
                },
                {
                    "first": "Alessandra",
                    "initial": "A.",
                    "last": "Martini"
                },
                {
                    "first": "Ruxandra",
                    "initial": "R.",
                    "last": "Draghia-Akli"
                }
            ],
            "doi": "10.1016/j.vaccine.2016.10.031",
            "firstpage": "A20",
            "issn": "0264410X",
            "lastpage": "A23",
            "pmid": "28017443",
            "pub_year": 2017,
            "title": "European strategy for vaccine development against infectious diseases",
            "volume": "35"
        },
        "b0200": {
            "authors": [
                {
                    "first": "John",
                    "initial": "J.",
                    "last": "Krogstie"
                },
                {
                    "first": "Guttorm",
                    "initial": "G.",
                    "last": "Sindre"
                },
                {
                    "first": "H\u00e5vard",
                    "initial": "H.",
                    "last": "J\u00f8rgensen"
                }
            ],
            "doi": "10.1057/palgrave.ejis.3000598",
            "firstpage": "91",
            "issn": "0960085X",
            "lastpage": "102",
            "pub_year": 2006,
            "title": "Process models representing knowledge for action: A revised quality framework",
            "volume": "15"
        },
        "b0205": {
            "authors": [
                {
                    "first": "Carolina dos S.",
                    "initial": "C.d.S.",
                    "last": "Ribeiro"
                },
                {
                    "first": "Martine Y.",
                    "initial": "M.Y.",
                    "last": "van Roode"
                },
                {
                    "first": "George B.",
                    "initial": "G.B.",
                    "last": "Haringhuizen"
                },
                {
                    "first": "Marion P.",
                    "initial": "M.P.",
                    "last": "Koopmans"
                },
                {
                    "first": "Eric",
                    "initial": "E.",
                    "last": "Claassen"
                },
                {
                    "first": "Linda H.M.",
                    "initial": "L.H.M.",
                    "last": "van de Burgwal"
                }
            ],
            "doi": "10.1371/journal.pone.0195885",
            "issn": "19326203",
            "pmid": "29718947",
            "pub_year": 2018,
            "title": "How ownership rights over microorganisms affect infectious disease control and innovation: A root-cause analysis of barriers to data sharing as experienced by key stakeholders",
            "volume": "13"
        },
        "b0210": {
            "authors": [
                {
                    "first": "M.",
                    "initial": "M.",
                    "last": "van den Nieuwboer"
                },
                {
                    "first": "L. H.M.",
                    "initial": "L.H.M.",
                    "last": "van de Burgwal"
                },
                {
                    "first": "E.",
                    "initial": "E.",
                    "last": "Claassen"
                }
            ],
            "doi": "10.1016/j.phanu.2015.09.003",
            "firstpage": "9",
            "issn": "22134344",
            "lastpage": "18",
            "pub_year": 2016,
            "title": "A quantitative key-opinion-leader analysis of innovation barriers in probiotic research and development: Valorisation and improving the tech transfer cycle",
            "volume": "4"
        },
        "b0215": {
            "authors": [
                {
                    "first": "Robert G.",
                    "initial": "R.G.",
                    "last": "Cooper"
                }
            ],
            "doi": "10.1111/j.1540-5885.2008.00296.x",
            "firstpage": "213",
            "issn": "07376782",
            "lastpage": "232",
            "pub_year": 2008,
            "title": "Perspective: The stage-gates\u00ae idea-to-launch process - Update, what's new, and NexGen systems",
            "volume": "25"
        },
        "b0220": {
            "authors": [
                {
                    "first": "Robert G.",
                    "initial": "R.G.",
                    "last": "Cooper"
                }
            ],
            "doi": "10.5437/08956308X5606963",
            "firstpage": "20",
            "issn": "08956308",
            "lastpage": "31",
            "pub_year": 2014,
            "title": "What's next? After stage-gate",
            "volume": "57"
        },
        "b0225": null,
        "b0230": null,
        "b0235": {
            "authors": [
                {
                    "first": "Hsiu Fang",
                    "initial": "H.F.",
                    "last": "Hsieh"
                },
                {
                    "first": "Sarah E.",
                    "initial": "S.E.",
                    "last": "Shannon"
                }
            ],
            "doi": "10.1177/1049732305276687",
            "firstpage": "1277",
            "issn": "10497323",
            "lastpage": "1288",
            "pmid": "16204405",
            "pub_year": 2005,
            "title": "Three approaches to qualitative content analysis",
            "volume": "15"
        },
        "b0240": {
            "authors": [
                {
                    "first": "Hajo A.",
                    "initial": "H.A.",
                    "last": "Reijers"
                },
                {
                    "first": "Jan",
                    "initial": "J.",
                    "last": "Mendling"
                },
                {
                    "first": "Jan",
                    "initial": "J.",
                    "last": "Recker"
                }
            ],
            "doi": "10.1007/978-3-642-45100-3_8",
            "firstpage": "167",
            "lastpage": "185",
            "pub_year": 2015,
            "title": "Business process quality management"
        },
        "b0245": {
            "authors": [
                {
                    "first": "Colleen",
                    "initial": "C.",
                    "last": "Cook"
                },
                {
                    "first": "Fred",
                    "initial": "F.",
                    "last": "Heath"
                },
                {
                    "first": "Russel L.",
                    "initial": "R.L.",
                    "last": "Thompson"
                }
            ],
            "doi": "10.1177/00131640021970934",
            "firstpage": "821",
            "issn": "00131644",
            "lastpage": "836",
            "pub_year": 2000,
            "title": "A meta-analysis of response rates in Web- or internet-based surveys",
            "volume": "60"
        },
        "b0250": {
            "authors": [
                {
                    "first": "Yehuda",
                    "initial": "Y.",
                    "last": "Baruch"
                },
                {
                    "first": "Brooks C.",
                    "initial": "B.C.",
                    "last": "Holtom"
                }
            ],
            "doi": "10.1177/0018726708094863",
            "firstpage": "1139",
            "issn": "00187267",
            "lastpage": "1160",
            "pub_year": 2008,
            "title": "Survey response rate levels and trends in organizational research",
            "volume": "61"
        },
        "b0255": {
            "authors": [
                {
                    "first": "Jon",
                    "initial": "J.",
                    "last": "Smith"
                },
                {
                    "first": "Marc",
                    "initial": "M.",
                    "last": "Lipsitch"
                },
                {
                    "first": "Jeffrey W.",
                    "initial": "J.W.",
                    "last": "Almond"
                }
            ],
            "doi": "10.1016/S0140-6736(11)60478-9",
            "firstpage": "428",
            "issn": "01406736",
            "lastpage": "438",
            "pmid": "21664680",
            "pub_year": 2011,
            "title": "Vaccine production, distribution, access, and uptake",
            "volume": "378"
        },
        "b0260": {
            "authors": [
                {
                    "first": "James M.",
                    "initial": "J.M.",
                    "last": "Robinson"
                }
            ],
            "doi": "10.1016/B978-0-12-802174-3.00005-9",
            "firstpage": "77",
            "lastpage": "96",
            "pub_year": 2016,
            "title": "Vaccine Production: Main Steps and Considerations"
        },
        "b0265": null,
        "b0270": {
            "authors": [
                {
                    "first": "Anthony L.",
                    "initial": "A.L.",
                    "last": "Cunningham"
                },
                {
                    "first": "Nathalie",
                    "initial": "N.",
                    "last": "Gar\u00e7on"
                },
                {
                    "first": "Oberdan",
                    "initial": "O.",
                    "last": "Leo"
                },
                {
                    "first": "Leonard R.",
                    "initial": "L.R.",
                    "last": "Friedland"
                },
                {
                    "first": "Richard",
                    "initial": "R.",
                    "last": "Strugnell"
                },
                {
                    "first": "B\u00e9atrice",
                    "initial": "B.",
                    "last": "Laup\u00e8ze"
                },
                {
                    "first": "Mark",
                    "initial": "M.",
                    "last": "Doherty"
                },
                {
                    "first": "Peter",
                    "initial": "P.",
                    "last": "Stern"
                }
            ],
            "doi": "10.1016/j.vaccine.2016.10.016",
            "firstpage": "6655",
            "issn": "0264410X",
            "lastpage": "6664",
            "pmid": "27769596",
            "pub_year": 2016,
            "title": "Vaccine development: From concept to early clinical testing",
            "volume": "34"
        },
        "b0275": {
            "authors": [
                {
                    "first": "Scott",
                    "initial": "S.",
                    "last": "Preiss"
                },
                {
                    "first": "Nathalie",
                    "initial": "N.",
                    "last": "Gar\u00e7on"
                },
                {
                    "first": "Anthony L.",
                    "initial": "A.L.",
                    "last": "Cunningham"
                },
                {
                    "first": "Richard",
                    "initial": "R.",
                    "last": "Strugnell"
                },
                {
                    "first": "Leonard R.",
                    "initial": "L.R.",
                    "last": "Friedland"
                }
            ],
            "doi": "10.1016/j.vaccine.2016.10.079",
            "firstpage": "6665",
            "issn": "0264410X",
            "lastpage": "6671",
            "pmid": "27884478",
            "pub_year": 2016,
            "title": "Vaccine provision: Delivering sustained & widespread use",
            "volume": "34"
        },
        "b0280": {
            "authors": [
                {
                    "first": "Karin",
                    "initial": "K.",
                    "last": "Hardt"
                },
                {
                    "first": "Paolo",
                    "initial": "P.",
                    "last": "Bonanni"
                },
                {
                    "first": "Susan",
                    "initial": "S.",
                    "last": "King"
                },
                {
                    "first": "Jose Ignacio",
                    "initial": "J.I.",
                    "last": "Santos"
                },
                {
                    "first": "Mostafa",
                    "initial": "M.",
                    "last": "El-Hodhod"
                },
                {
                    "first": "Gregory D.",
                    "initial": "G.D.",
                    "last": "Zimet"
                },
                {
                    "first": "Scott",
                    "initial": "S.",
                    "last": "Preiss"
                }
            ],
            "doi": "10.1016/j.vaccine.2016.10.078",
            "firstpage": "6691",
            "issn": "0264410X",
            "lastpage": "6699",
            "pmid": "27887796",
            "pub_year": 2016,
            "title": "Vaccine strategies: Optimising outcomes",
            "volume": "34"
        },
        "b0285": {
            "authors": [
                {
                    "first": "William H.A.",
                    "initial": "W.H.A.",
                    "last": "Johnson"
                }
            ],
            "doi": "10.1016/j.respol.2011.04.001",
            "firstpage": "842",
            "issn": "00487333",
            "lastpage": "852",
            "pub_year": 2011,
            "title": "Managing university technology development using organizational control theory",
            "volume": "40"
        },
        "b0290": {
            "authors": [
                {
                    "first": "Linda H.M.",
                    "initial": "L.H.M.",
                    "last": "Van De Burgwal"
                },
                {
                    "first": "Leslie A.",
                    "initial": "L.A.",
                    "last": "Reperant"
                },
                {
                    "first": "Albert D.M.E.",
                    "initial": "A.D.M.E.",
                    "last": "Osterhaus"
                },
                {
                    "first": "Sorana C.",
                    "initial": "S.C.",
                    "last": "Iancu"
                },
                {
                    "first": "Esther S.",
                    "initial": "E.S.",
                    "last": "Pronker"
                },
                {
                    "first": "Eric",
                    "initial": "E.",
                    "last": "Claassen"
                }
            ],
            "doi": "10.1017/dmp.2016.64",
            "firstpage": "644",
            "issn": "19357893",
            "lastpage": "648",
            "pmid": "27322192",
            "pub_year": 2016,
            "title": "Self-Centric and Altruistic Unmet Needs for Ebola: Barriers to International Preparedness",
            "volume": "10"
        },
        "b0295": {
            "authors": [
                {
                    "first": "Catherine",
                    "initial": "C.",
                    "last": "Gerdil"
                }
            ],
            "doi": "10.1016/S0264-410X(03)00071-9",
            "firstpage": "1776",
            "issn": "0264410X",
            "lastpage": "1779",
            "pmid": "12686093",
            "pub_year": 2003,
            "title": "The annual production cycle for influenza vaccine",
            "volume": "21"
        },
        "b0300": {
            "authors": [
                {
                    "first": "Guus",
                    "initial": "G.",
                    "last": "Berkhout"
                },
                {
                    "first": "Dap",
                    "initial": "D.",
                    "last": "Hartmann"
                },
                {
                    "first": "Paul",
                    "initial": "P.",
                    "last": "Trott"
                }
            ],
            "doi": "10.1111/j.1467-9310.2010.00618.x",
            "firstpage": "474",
            "issn": "00336807",
            "lastpage": "490",
            "pub_year": 2010,
            "title": "Connecting technological capabilities with market needs using a cyclic innovation model",
            "volume": "40"
        },
        "b0305": {
            "authors": [
                {
                    "first": "Andrew Q.",
                    "initial": "A.Q.",
                    "last": "Ford"
                },
                {
                    "first": "Nancy",
                    "initial": "N.",
                    "last": "Touchette"
                },
                {
                    "first": "B.",
                    "initial": "B.",
                    "last": "Fenton Hall"
                },
                {
                    "first": "Angela",
                    "initial": "A.",
                    "last": "Hwang"
                },
                {
                    "first": "Joachim",
                    "initial": "J.",
                    "last": "Hombach"
                }
            ],
            "doi": "10.1016/j.vaccine.2017.12.013",
            "firstpage": "915",
            "issn": "0264410X",
            "lastpage": "920",
            "pmid": "29338876",
            "pub_year": 2018,
            "title": "Meeting report: Global vaccine and immunization research forum",
            "volume": "36"
        },
        "b0310": {
            "authors": [
                {
                    "first": "Roy",
                    "initial": "R.",
                    "last": "Widdus"
                }
            ],
            "doi": "10.2471/BLT.10.082826",
            "firstpage": "880",
            "issn": "00429686",
            "pmid": "21124708",
            "pub_year": 2010,
            "title": "Vaccine innovation done differently",
            "volume": "88"
        },
        "b0315": {
            "authors": [
                {
                    "first": "Anne M.G.",
                    "initial": "A.M.G.",
                    "last": "Neevel"
                },
                {
                    "first": "Tessa",
                    "initial": "T.",
                    "last": "Hemrika"
                },
                {
                    "first": "Eric",
                    "initial": "E.",
                    "last": "Claassen"
                },
                {
                    "first": "Linda H.M.",
                    "initial": "L.H.M.",
                    "last": "van de Burgwal"
                }
            ],
            "doi": "10.1371/journal.pntd.0006387",
            "issn": "19352727",
            "pmid": "29727444",
            "pub_year": 2018,
            "title": "A research agenda to reinforce rabies control: A qualitative and quantitative prioritization",
            "volume": "12"
        },
        "b0320": {
            "authors": [
                {
                    "first": "L. H.M.",
                    "initial": "L.H.M.",
                    "last": "van de Burgwal"
                },
                {
                    "first": "A. M.G.",
                    "initial": "A.M.G.",
                    "last": "Neevel"
                },
                {
                    "first": "C. A.C.M.",
                    "initial": "C.A.C.M.",
                    "last": "Pittens"
                },
                {
                    "first": "A. D.M.E.",
                    "initial": "A.D.M.E.",
                    "last": "Osterhaus"
                },
                {
                    "first": "C. E.",
                    "initial": "C.E.",
                    "last": "Rupprecht"
                },
                {
                    "first": "E.",
                    "initial": "E.",
                    "last": "Claassen"
                }
            ],
            "doi": "10.1111/zph.12352",
            "firstpage": "599",
            "issn": "18631959",
            "lastpage": "611",
            "pmid": "28318148",
            "pub_year": 2017,
            "title": "Barriers to innovation in human rabies prophylaxis and treatment: A causal analysis of insights from key opinion leaders and literature",
            "volume": "64"
        }
    },
    "body_text": [
        {
            "endOffset": 55089,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Results"
                },
                {
                    "id": "s0040",
                    "title": "Description of stages and gates"
                }
            ],
            "secId": "s0045",
            "sentence": "For instance, successful completion of the CMC gate is linked to preclinical development steps and the preparation of manufacturing should be completed before clinical trials are started.",
            "startOffset": 54902,
            "title": "Stages and gates at defined loci"
        },
        {
            "endOffset": 45088,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0015",
            "sentence": "Here the combination of the stage-gate model and the VTTC was used to describe the activities and relevant criteria in the vaccine innovation process.",
            "startOffset": 44938,
            "title": "Conceptual framework"
        },
        {
            "endOffset": 59179,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "Throughout these gates adequate product performance is a prominent checkpoint.",
            "startOffset": 59101,
            "title": "Gate criteria"
        },
        {
            "endOffset": 49493,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0030",
            "sentence": "The resulting description of the vaccine innovation process was validated through a survey among KOLs.",
            "startOffset": 49391,
            "title": "Survey"
        },
        {
            "endOffset": 59508,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "A detailed overview of external criteria per gate is provided in Supplementary Material 3.",
            "startOffset": 59418,
            "title": "Gate criteria"
        },
        {
            "endOffset": 63284,
            "parents": [],
            "refoffsets": {
                "b0285": {
                    "endOffset": 63283,
                    "startOffset": 63279
                }
            },
            "secId": "s0065",
            "sentence": "In the latter case, the societal relevance of explorative research may be optimised [57].",
            "startOffset": 63195,
            "title": "Discussion"
        },
        {
            "endOffset": 63526,
            "parents": [],
            "refoffsets": {
                "b0290": {
                    "endOffset": 63525,
                    "startOffset": 63521
                }
            },
            "secId": "s0065",
            "sentence": "As an example, a recent study argued that differential articulations of medical, societal and technical unmet needs were likely to result in mismatches in resource allocation and delays in adequate responses to the 2014 Ebola outbreaks [58].",
            "startOffset": 63285,
            "title": "Discussion"
        },
        {
            "endOffset": 46903,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0025",
            "sentence": "Detailed information included the study aim, central concepts and interview structure.",
            "startOffset": 46817,
            "title": "Interviews"
        },
        {
            "endOffset": 65005,
            "parents": [],
            "secId": "s0065",
            "sentence": "From there they continue their innovation efforts throughout the cycle.",
            "startOffset": 64934,
            "title": "Discussion"
        },
        {
            "endOffset": 37915,
            "parents": [],
            "refoffsets": {
                "b0105": {
                    "endOffset": 37914,
                    "startOffset": 37910
                }
            },
            "secId": "s0005",
            "sentence": "Indeed, SMEs bridge R&D gaps between basic discovery and early clinical development and large companies build upon this progress to meet regulatory demands [21].",
            "startOffset": 37754,
            "title": "Introduction"
        },
        {
            "endOffset": 53875,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Results"
                }
            ],
            "secId": "s0040",
            "sentence": "In an integrated product development process, the different defined, undefined and monitoring stage-gates occurred in parallel workstreams and outcomes in one workstream influenced decision-making in other workstreams.",
            "startOffset": 53657,
            "title": "Description of stages and gates"
        },
        {
            "endOffset": 40564,
            "parents": [],
            "refoffsets": {
                "b0080": {
                    "endOffset": 40563,
                    "startOffset": 40550
                },
                "b0105": {
                    "endOffset": 40563,
                    "startOffset": 40550
                },
                "b0190": {
                    "endOffset": 40563,
                    "startOffset": 40550
                },
                "b0195": {
                    "endOffset": 40563,
                    "startOffset": 40550
                }
            },
            "secId": "s0005",
            "sentence": "Public and private stakeholders from academia, public health institutes, regulators, industry, SMEs, health care professionals, vaccine users, and policymakers, therefore have to bridge their own perspective in order to effectively collaborate with each other [16,21,38,39].",
            "startOffset": 40290,
            "title": "Introduction"
        },
        {
            "endOffset": 40157,
            "parents": [],
            "refoffsets": {
                "b0100": {
                    "endOffset": 40046,
                    "startOffset": 40042
                }
            },
            "secId": "s0005",
            "sentence": "However, whereas some have identified that the vaccine industry evaluates the business case and the scientific feasibility to set priorities for R&D [20], a thorough description of criteria used to evaluate the progress of vaccine innovation activities is lacking.",
            "startOffset": 39893,
            "title": "Introduction"
        },
        {
            "endOffset": 53164,
            "parents": [],
            "secId": "s0035",
            "sentence": "The initial description of stage-gates was refined with comments gathered from the survey, and a final description of each stage and its corresponding gate, organized in ten different but integrated workstreams, is provided in Section 3.1.",
            "startOffset": 52925,
            "title": "Results"
        },
        {
            "endOffset": 46105,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0020",
            "sentence": "Firstly, a search for invited guest speakers at international symposia was conducted; secondly, a search for senior level professionals was conducted on the websites of large organizations active in vaccine innovation; and thirdly, a strategy of snowball sampling was adopted, in which participants were asked to identify additional KOLs from their network to participate in the current study.",
            "startOffset": 45712,
            "title": "Interview respondents"
        },
        {
            "endOffset": 54631,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Results"
                },
                {
                    "id": "s0040",
                    "title": "Description of stages and gates"
                }
            ],
            "secId": "s0045",
            "sentence": "Defined stages and gates comprise three groups of activities that consist of sequential steps but run in parallel: (1) research and development, (2) Good Manufacturing Practice (GMP) production and (3) market preparation, registration and introduction.",
            "startOffset": 54379,
            "title": "Stages and gates at defined loci"
        },
        {
            "endOffset": 38690,
            "parents": [],
            "secId": "s0005",
            "sentence": "The importance of collaboration extends into the development of agreed evidence to inform novel licensure pathways and overall policy recommendations and even beyond to design post-marketing surveillance.",
            "startOffset": 38486,
            "title": "Introduction"
        },
        {
            "endOffset": 69372,
            "parents": [],
            "secId": "s0065",
            "sentence": "In this sense, the VIC is a descriptive model, describing which stage-gates are seen as vital aspects of vaccine innovation, rather than a prescriptive model that determines which criteria should be taken into account in an ideal world.",
            "startOffset": 69136,
            "title": "Discussion"
        },
        {
            "endOffset": 36173,
            "parents": [],
            "refoffsets": {
                "b0030": {
                    "endOffset": 36172,
                    "startOffset": 36169
                }
            },
            "secId": "s0005",
            "sentence": "So far, 26 infectious diseases have been targeted by vaccines, and 24 other diseases have been the focus of vaccine development [6].",
            "startOffset": 36041,
            "title": "Introduction"
        },
        {
            "endOffset": 37286,
            "parents": [],
            "refoffsets": {
                "b0090": {
                    "endOffset": 37082,
                    "startOffset": 37078
                },
                "b0095": {
                    "endOffset": 37152,
                    "startOffset": 37148
                },
                "b0100": {
                    "endOffset": 37285,
                    "startOffset": 37281
                }
            },
            "secId": "s0005",
            "sentence": "With substantial investments needed to obtain this wide variety of expertise [18] and the significant uncertainty accompanying vaccine development [19], only a handful of large companies have managed to accumulate the resources needed for bringing vaccines into market deployment [20].",
            "startOffset": 37001,
            "title": "Introduction"
        },
        {
            "endOffset": 47604,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "refoffsets": {
                "b0230": {
                    "endOffset": 47603,
                    "startOffset": 47599
                }
            },
            "secId": "s0025",
            "sentence": "This ensured a broadly similar structure among the various interviewees while allowing for follow-up questions to appear during the course of the interview to obtain information as in-depth as possible [46].",
            "startOffset": 47397,
            "title": "Interviews"
        },
        {
            "endOffset": 39736,
            "parents": [],
            "refoffsets": {
                "b0155": {
                    "endOffset": 39735,
                    "startOffset": 39728
                },
                "b0160": {
                    "endOffset": 39735,
                    "startOffset": 39728
                }
            },
            "secId": "s0005",
            "sentence": "As a consequence, stakeholders from different domains might lack reciprocal understanding and appreciation of each other\u2019s significance in optimizing the innovation process [31,32].",
            "startOffset": 39555,
            "title": "Introduction"
        },
        {
            "endOffset": 41095,
            "parents": [],
            "refoffsets": {
                "b0045": {
                    "endOffset": 41094,
                    "startOffset": 41091
                }
            },
            "secId": "s0005",
            "sentence": "Existing models within the vaccine industry, however, do not provide the necessary level of detail for all stakeholders to understand their respective contribution in the innovation processes [9].",
            "startOffset": 40899,
            "title": "Introduction"
        },
        {
            "endOffset": 46816,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0025",
            "sentence": "Participants were contacted via e-mail, informed about the nature of the study and invited to take part.",
            "startOffset": 46712,
            "title": "Interviews"
        },
        {
            "endOffset": 58165,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Results"
                },
                {
                    "id": "s0040",
                    "title": "Description of stages and gates"
                }
            ],
            "secId": "s0055",
            "sentence": "Moreover, gates are less formal and at times represent outcomes of certain activities rather than fixed criteria against which deliverables of activities are evaluated.",
            "startOffset": 57997,
            "title": "Monitoring stages and gates"
        },
        {
            "endOffset": 54765,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Results"
                },
                {
                    "id": "s0040",
                    "title": "Description of stages and gates"
                }
            ],
            "secId": "s0045",
            "sentence": "Within these groups of defined stages and gates, successful completion of gates is necessary before a subsequent stage can be started.",
            "startOffset": 54631,
            "title": "Stages and gates at defined loci"
        },
        {
            "endOffset": 39554,
            "parents": [],
            "refoffsets": {
                "b0150": {
                    "endOffset": 39553,
                    "startOffset": 39549
                }
            },
            "secId": "s0005",
            "sentence": "One of these challenges is related to the specialization of expertise in silos, leading stakeholders to have in-depth insight into their own set of activities while failing to understand the complexity of the total value chain [30].",
            "startOffset": 39322,
            "title": "Introduction"
        },
        {
            "endOffset": 61100,
            "parents": [],
            "secId": "s0065",
            "sentence": "Next to the conventional research and development stage-gates of vaccine development, this study provides stage-gates for nine additional types of activities that are essential for successful vaccine innovation.",
            "startOffset": 60889,
            "title": "Discussion"
        },
        {
            "endOffset": 53939,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Results"
                }
            ],
            "secId": "s0040",
            "sentence": "In addition, some stages were executed in an iterative fashion.",
            "startOffset": 53876,
            "title": "Description of stages and gates"
        },
        {
            "endOffset": 43895,
            "parents": [],
            "secId": "s0010",
            "sentence": "After data analysis and the compilation of a first draft of an integrated model, survey responses from 46 KOLs were collected and their feedback was incorporated into a final version of the Vaccine Innovation Cycle (VIC).",
            "startOffset": 43674,
            "title": "Methodology"
        },
        {
            "endOffset": 63957,
            "parents": [],
            "secId": "s0065",
            "sentence": "Most new vaccines are incremental innovations and therefore part of a circular value chain for similar product-market combinations.",
            "startOffset": 63826,
            "title": "Discussion"
        },
        {
            "endOffset": 45451,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0015",
            "sentence": "The combination and integration of the stage-gate model with the VTTC has the potential to address the persistent need of a complete and contextualized conceptual model representing the vaccine innovation process, by describing its activities per stage-gate and therefore providing a complete overview of all steps and criteria in the vaccine innovation process.",
            "startOffset": 45089,
            "title": "Conceptual framework"
        },
        {
            "endOffset": 58460,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Results"
                },
                {
                    "id": "s0040",
                    "title": "Description of stages and gates"
                }
            ],
            "secId": "s0055",
            "sentence": "Here, each group refers to the focus of the activities.",
            "startOffset": 58405,
            "title": "Monitoring stages and gates"
        },
        {
            "endOffset": 48874,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0025",
            "sentence": "In this process, text fragments were coded and categories were deductively derived from the data.",
            "startOffset": 48777,
            "title": "Interviews"
        },
        {
            "endOffset": 50358,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0030",
            "sentence": "To enable high-quality input, respondents were asked to indicate to which domain their expertise related the most.",
            "startOffset": 50244,
            "title": "Survey"
        },
        {
            "endOffset": 55625,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Results"
                },
                {
                    "id": "s0040",
                    "title": "Description of stages and gates"
                }
            ],
            "secId": "s0045",
            "sentence": "Moreover, as indicated by some of the respondents the exact timing of parallel processes is contingent on contextual factors.",
            "startOffset": 55500,
            "title": "Stages and gates at defined loci"
        },
        {
            "endOffset": 40898,
            "parents": [],
            "refoffsets": {
                "b0200": {
                    "endOffset": 40897,
                    "startOffset": 40893
                }
            },
            "secId": "s0005",
            "sentence": "Such models have been shown to improve stakeholder collaboration and efficiency in many sectors [40].",
            "startOffset": 40797,
            "title": "Introduction"
        },
        {
            "endOffset": 48536,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0025",
            "sentence": "In addition, they were summarized and sent to the interviewee for confirmation and optional comments or modifications.",
            "startOffset": 48418,
            "title": "Interviews"
        },
        {
            "endOffset": 46343,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0020",
            "sentence": "Background analyses were conducted before reaching out to potential interviewees.",
            "startOffset": 46262,
            "title": "Interview respondents"
        },
        {
            "endOffset": 51871,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0030",
            "sentence": "All data were treated confidentially and were processed anonymously.",
            "startOffset": 51803,
            "title": "Survey"
        },
        {
            "endOffset": 57996,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Results"
                },
                {
                    "id": "s0040",
                    "title": "Description of stages and gates"
                }
            ],
            "secId": "s0055",
            "sentence": "Monitoring stage-gates take place in a continuous and iterative manner, rather than being preceded by the finalization of a previous stage-gate.",
            "startOffset": 57852,
            "title": "Monitoring stages and gates"
        },
        {
            "endOffset": 69911,
            "parents": [],
            "secId": "s0070",
            "sentence": "The resulting model can be used by all key stakeholders to evaluate how their activities relate to those of others and to facilitate cross-learning, understanding and appreciation among stakeholders.",
            "startOffset": 69712,
            "title": "Conclusion"
        },
        {
            "endOffset": 68201,
            "parents": [],
            "refoffsets": {
                "b0140": {
                    "endOffset": 68066,
                    "startOffset": 68059
                },
                "b0290": {
                    "endOffset": 68066,
                    "startOffset": 68059
                },
                "b0315": {
                    "endOffset": 68085,
                    "startOffset": 68078
                },
                "b0320": {
                    "endOffset": 68085,
                    "startOffset": 68078
                }
            },
            "secId": "s0065",
            "sentence": "As shown before for Ebola [28,58] and rabies [63,64], vaccine innovation for developing countries is primarily guided by public perception and political prioritization.",
            "startOffset": 68033,
            "title": "Discussion"
        },
        {
            "endOffset": 45711,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0020",
            "sentence": "KOLs were identified in three distinct ways.",
            "startOffset": 45667,
            "title": "Interview respondents"
        },
        {
            "endOffset": 69711,
            "parents": [],
            "secId": "s0070",
            "sentence": "The integrated, actor- and domain-transcending perspective of the VIC provides a comprehensive view on the necessary stages and relevant criteria for successful progression through the vaccine value chain.",
            "startOffset": 69506,
            "title": "Conclusion"
        },
        {
            "endOffset": 42146,
            "parents": [],
            "refoffsets": {
                "b0055": {
                    "endOffset": 42017,
                    "startOffset": 42007
                },
                "b0205": {
                    "endOffset": 42017,
                    "startOffset": 42007
                },
                "b0210": {
                    "endOffset": 42017,
                    "startOffset": 42007
                }
            },
            "secId": "s0005",
            "sentence": "In contrast to the PVC and the 4DM, the Valorisation and Technology Transfer Cycle (VTTC) [11,41,42] is a circular model that includes market and society domains feeding into science and business development domains (see Fig. 1).",
            "startOffset": 41917,
            "title": "Introduction"
        },
        {
            "endOffset": 44937,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "refoffsets": {
                "b0215": {
                    "endOffset": 44936,
                    "startOffset": 44932
                }
            },
            "secId": "s0015",
            "sentence": "The comparison of the stages\u2019 deliverables against gates\u2019 criteria results in an outcome to progress, recycle, kill or hold the project, thereby decreasing the project\u2019s uncertainties and risks [43].",
            "startOffset": 44738,
            "title": "Conceptual framework"
        },
        {
            "endOffset": 65486,
            "parents": [],
            "refoffsets": {
                "b0300": {
                    "endOffset": 65485,
                    "startOffset": 65481
                }
            },
            "secId": "s0065",
            "sentence": "This is conceptualized through the lack of a clear starting point in the cycle; innovations can start anywhere and from there continue their way through the innovation stage-gates, as was shown in the Cyclic Innovation Model [60].",
            "startOffset": 65256,
            "title": "Discussion"
        },
        {
            "endOffset": 52664,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0030",
            "sentence": "The criteria were analysed for their occurrence in different gates and a gap-overlap analysis of internal and external criteria was conducted.",
            "startOffset": 52522,
            "title": "Survey"
        },
        {
            "endOffset": 53656,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Results"
                }
            ],
            "secId": "s0040",
            "sentence": "Yet other stages occurred continuously throughout the vaccine innovation process and were classified as \u201cmonitoring\u201d stage-gates.",
            "startOffset": 53527,
            "title": "Description of stages and gates"
        },
        {
            "endOffset": 56265,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Results"
                },
                {
                    "id": "s0040",
                    "title": "Description of stages and gates"
                }
            ],
            "secId": "s0050",
            "sentence": "The stages and gates are grouped in two separate types of activities.",
            "startOffset": 56196,
            "title": "Stages and gates at undefined loci"
        },
        {
            "endOffset": 60568,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "These criteria ensure that the vaccine candidate progresses through the external checkpoints.",
            "startOffset": 60475,
            "title": "Gate criteria"
        },
        {
            "endOffset": 41591,
            "parents": [],
            "refoffsets": {
                "b0170": {
                    "endOffset": 41518,
                    "startOffset": 41514
                }
            },
            "secId": "s0005",
            "sentence": "The recently developed \u201cDrug Discovery, Development and Deployment Maps (4DM)\u201d provides a more thorough representation of therapeutic development processes for biologicals [34] but leaves out non-technical processes and is not specific for vaccines.",
            "startOffset": 41342,
            "title": "Introduction"
        },
        {
            "endOffset": 61253,
            "parents": [],
            "secId": "s0065",
            "sentence": "The cyclical nature of the VIC highlights the importance of synchronizing with unmet needs, market changes, existing expertise and quality improvements.",
            "startOffset": 61101,
            "title": "Discussion"
        },
        {
            "endOffset": 49936,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0030",
            "sentence": "The sampling included the identification of experts who (1) participated as a guest speaker on international vaccine conferences in 2017; (2) were a member of the Strategic Advisory Group of Experts on Immunization (SAGE) for the WHO in the period 2012\u20132016 or (3) were mentioned as influencer of immunization programs across the globe on a blog by the Bill and Melinda Gates foundation in 2013.",
            "startOffset": 49541,
            "title": "Survey"
        },
        {
            "endOffset": 68710,
            "parents": [],
            "secId": "s0065",
            "sentence": "For instance, depending on the context, outcomes from monitoring gates may include project adjustments rather than strict go/no-go outcomes.",
            "startOffset": 68570,
            "title": "Discussion"
        },
        {
            "endOffset": 62686,
            "parents": [],
            "secId": "s0065",
            "sentence": "Importantly, the VIC highlights that whereas some activities in vaccine innovation take place in clearly defined and sequential workstreams (defined stages and gates), the occurrence and timing of other activities is contingent on contextual factors (undefined stages and gates) and yet other activities take place continuously within a certain range (monitoring stages and gates).",
            "startOffset": 62305,
            "title": "Discussion"
        },
        {
            "endOffset": 67720,
            "parents": [],
            "secId": "s0065",
            "sentence": "This discrepancy may in part be explained by our decision to focus on criteria for vaccines for developed countries, where constraints to market feasibility are less prominent.",
            "startOffset": 67544,
            "title": "Discussion"
        },
        {
            "endOffset": 58532,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Results"
                },
                {
                    "id": "s0040",
                    "title": "Description of stages and gates"
                }
            ],
            "secId": "s0055",
            "sentence": "A description of each of these stages and gates is provided in Table 3.",
            "startOffset": 58461,
            "title": "Monitoring stages and gates"
        },
        {
            "endOffset": 36507,
            "parents": [],
            "refoffsets": {
                "b0045": {
                    "endOffset": 36425,
                    "startOffset": 36422
                }
            },
            "secId": "s0005",
            "sentence": "This \u2018vaccine innovation paradox\u2019 [9] is in part inherent to the complex and challenging nature of vaccine development.",
            "startOffset": 36388,
            "title": "Introduction"
        },
        {
            "endOffset": 70442,
            "parents": [],
            "secId": "s0070",
            "sentence": "Considering the different levels of understanding of the total value cycle, herewith we hope to improve both understanding and communication in forming collaborative alliances and partnerships between public and private partners to accelerate vaccine innovation processes.",
            "startOffset": 70170,
            "title": "Conclusion"
        },
        {
            "endOffset": 57820,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Results"
                },
                {
                    "id": "s0040",
                    "title": "Description of stages and gates"
                }
            ],
            "secId": "s0050",
            "sentence": "The undefined gates within the funding and business development group may require successful completion of one or multiple other stages but this is dependent on contextual factors.",
            "startOffset": 57640,
            "title": "Stages and gates at undefined loci"
        },
        {
            "endOffset": 44737,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0015",
            "sentence": "The stage-gate model thus distinguishes stages, as periods in time during which information gathering activities are turned into deliverables; and gates, as the evaluation and decision-making moments following each stage.",
            "startOffset": 44516,
            "title": "Conceptual framework"
        },
        {
            "endOffset": 64294,
            "parents": [],
            "secId": "s0065",
            "sentence": "In some other cases, development of novel vaccines is accelerated due to the identification of correlates of protection in the clinical setting.",
            "startOffset": 64150,
            "title": "Discussion"
        },
        {
            "endOffset": 54043,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Results"
                },
                {
                    "id": "s0040",
                    "title": "Description of stages and gates"
                }
            ],
            "secId": "s0045",
            "sentence": "More than half of the identified stage-gates occur at defined loci.",
            "startOffset": 53976,
            "title": "Stages and gates at defined loci"
        },
        {
            "endOffset": 57639,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Results"
                },
                {
                    "id": "s0040",
                    "title": "Description of stages and gates"
                }
            ],
            "secId": "s0050",
            "sentence": "Importantly, manufacturing only starts once the preparation of manufacturing stage (S11) is successfully completed.",
            "startOffset": 57524,
            "title": "Stages and gates at undefined loci"
        },
        {
            "endOffset": 59307,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "Other prominent checkpoints include adequate product quality, adequate relevance/unmet need and adequate clinical trial design.",
            "startOffset": 59180,
            "title": "Gate criteria"
        },
        {
            "endOffset": 59761,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "Internal criteria are used by stakeholders contributing to vaccine innovation to ensure that the vaccine candidate makes sufficient progress through internal gates before further resources are committed and/or they are submitted for external evaluation.",
            "startOffset": 59508,
            "title": "Gate criteria"
        },
        {
            "endOffset": 52830,
            "parents": [],
            "secId": "s0035",
            "sentence": "Building upon the proposed conceptual model, the interviewees indicated 20 stages and 26 gates that occurred throughout the value chain of vaccine innovation.",
            "startOffset": 52672,
            "title": "Results"
        },
        {
            "endOffset": 60888,
            "parents": [],
            "secId": "s0065",
            "sentence": "Here we find 29 distinct stages and 28 corresponding gates that describe the vaccine innovation process in ten distinct but integrated workstreams.",
            "startOffset": 60741,
            "title": "Discussion"
        },
        {
            "endOffset": 55824,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Results"
                },
                {
                    "id": "s0040",
                    "title": "Description of stages and gates"
                }
            ],
            "secId": "s0045",
            "sentence": "In industry, for example, CMC is typically finished before early stage preclinical studies are started, whereas universities and SMEs only prioritize this gate during late-stage preclinical studies.",
            "startOffset": 55626,
            "title": "Stages and gates at defined loci"
        },
        {
            "endOffset": 46610,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0020",
            "sentence": "KOLs wished to remain anonymous due to confidentiality concerns and therefore an anonymized list of KOLs is provided in Supplementary File 1.",
            "startOffset": 46469,
            "title": "Interview respondents"
        },
        {
            "endOffset": 37389,
            "parents": [],
            "refoffsets": {
                "b0105": {
                    "endOffset": 37388,
                    "startOffset": 37384
                }
            },
            "secId": "s0005",
            "sentence": "Small- and medium-sized companies (SMEs) rarely progress to later phases of clinical development [21].",
            "startOffset": 37287,
            "title": "Introduction"
        },
        {
            "endOffset": 43149,
            "parents": [],
            "refoffsets": {
                "b0200": {
                    "endOffset": 43148,
                    "startOffset": 43144
                }
            },
            "secId": "s0005",
            "sentence": "More importantly, considering the interdependencies the different domains, such insight can help actors to anticipate needs, constraints and requirements in early development stages, influencing their ability to decide on resource allocation and continuity of innovation projects in an integrated product development approach [40].",
            "startOffset": 42818,
            "title": "Introduction"
        },
        {
            "endOffset": 55950,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Results"
                },
                {
                    "id": "s0040",
                    "title": "Description of stages and gates"
                }
            ],
            "secId": "s0050",
            "sentence": "Undefined stages and gates occur adjacent to defined, core innovation stages and gates.",
            "startOffset": 55863,
            "title": "Stages and gates at undefined loci"
        },
        {
            "endOffset": 66757,
            "parents": [],
            "refoffsets": {
                "b0100": {
                    "endOffset": 66756,
                    "startOffset": 66752
                }
            },
            "secId": "s0065",
            "sentence": "This emphasizes the need for the vaccine industry to monitor their \u2018bottom line\u2019 and long-term viability before investing resources in developing vaccines that meet external unmet needs [20].",
            "startOffset": 66566,
            "title": "Discussion"
        },
        {
            "endOffset": 58817,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "Next to identifying and grouping stage-gates involved in vaccine development, an analysis of the criteria employed in each stage-gate was conducted.",
            "startOffset": 58669,
            "title": "Gate criteria"
        },
        {
            "endOffset": 36387,
            "parents": [],
            "refoffsets": {
                "b0035": {
                    "endOffset": 36386,
                    "startOffset": 36381
                },
                "b0040": {
                    "endOffset": 36386,
                    "startOffset": 36381
                }
            },
            "secId": "s0005",
            "sentence": "Despite these continuing efforts, product innovation is far from efficient and increased investments in research and development (R&D) are not followed by an increase in new market entries of novel vaccines [7,8].",
            "startOffset": 36174,
            "title": "Introduction"
        },
        {
            "endOffset": 38318,
            "parents": [],
            "refoffsets": {
                "b0120": {
                    "endOffset": 38317,
                    "startOffset": 38313
                }
            },
            "secId": "s0005",
            "sentence": "Moreover, in the context of radical innovation, collaboration with and between scientists from a wide variety of disciplines is essential to build upon recent advances [24].",
            "startOffset": 38145,
            "title": "Introduction"
        },
        {
            "endOffset": 39892,
            "parents": [],
            "refoffsets": {
                "b0165": {
                    "endOffset": 39891,
                    "startOffset": 39884
                },
                "b0170": {
                    "endOffset": 39891,
                    "startOffset": 39884
                }
            },
            "secId": "s0005",
            "sentence": "To better comprehend decision-making, insight into the accompanying criteria and societal needs that are used to evaluate these steps is necessary [33,34].",
            "startOffset": 39737,
            "title": "Introduction"
        },
        {
            "endOffset": 46261,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "refoffsets": {
                "b0225": {
                    "endOffset": 46165,
                    "startOffset": 46161
                }
            },
            "secId": "s0020",
            "sentence": "Respondents were identified through purposive sampling [45], enabling the selection of KOLs from all domains represented in the vaccine innovation process.",
            "startOffset": 46106,
            "title": "Interview respondents"
        },
        {
            "endOffset": 61854,
            "parents": [],
            "refoffsets": {
                "b0150": {
                    "endOffset": 61853,
                    "startOffset": 61843
                },
                "b0255": {
                    "endOffset": 61853,
                    "startOffset": 61843
                },
                "b0260": {
                    "endOffset": 61853,
                    "startOffset": 61843
                },
                "b0265": {
                    "endOffset": 61853,
                    "startOffset": 61843
                }
            },
            "secId": "s0065",
            "sentence": "Existing studies mainly describe the conventional and defined stage-gates of vaccine R&D and much focus is placed on the complexity of manufacturing [30,51\u201353].",
            "startOffset": 61694,
            "title": "Discussion"
        },
        {
            "endOffset": 47787,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0025",
            "sentence": "The topic list included a number of proposed stages and gates per domain, emphasising and therefore starting with the domain to which the expertise of the concerned KOL related most.",
            "startOffset": 47605,
            "title": "Interviews"
        },
        {
            "endOffset": 48659,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0025",
            "sentence": "Finalised transcripts were examined thoroughly, while text fragments that appeared important to the study were underlined.",
            "startOffset": 48537,
            "title": "Interviews"
        },
        {
            "endOffset": 52924,
            "parents": [],
            "secId": "s0035",
            "sentence": "In the survey, these were further refined into 29 distinct stages and 28 corresponding gates.",
            "startOffset": 52831,
            "title": "Results"
        },
        {
            "endOffset": 56195,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Results"
                },
                {
                    "id": "s0040",
                    "title": "Description of stages and gates"
                }
            ],
            "secId": "s0050",
            "sentence": "Their occurrence and timing is contingent on a wide variety of factors, including the context in which the innovation project was initiated, changes in development and market landscapes and the specific characteristics of the vaccine candidate.",
            "startOffset": 55951,
            "title": "Stages and gates at undefined loci"
        },
        {
            "endOffset": 47084,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0025",
            "sentence": "These introductionary topics were covered at the start of the interview as well, while participants were given the opportunity to state ambiguities and ask questions on the matter.",
            "startOffset": 46904,
            "title": "Interviews"
        },
        {
            "endOffset": 53380,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Results"
                }
            ],
            "secId": "s0040",
            "sentence": "These stage-gates were classified as \u201cdefined\u201d.",
            "startOffset": 53333,
            "title": "Description of stages and gates"
        },
        {
            "endOffset": 41341,
            "parents": [],
            "secId": "s0005",
            "sentence": "The well-known pharmaceutical value chain (PVC) provides a linear description of R&D stages for pharmaceutical compounds from target to launch but doesn\u2019t provide insight into the accompanying processes such as manufacturing and market feedback.",
            "startOffset": 41096,
            "title": "Introduction"
        },
        {
            "endOffset": 61693,
            "parents": [],
            "secId": "s0065",
            "sentence": "The current study comprehensively describes the activities and criteria in vaccine development per stage-gate as perceived by KOLs.",
            "startOffset": 61562,
            "title": "Discussion"
        },
        {
            "endOffset": 42510,
            "parents": [],
            "secId": "s0005",
            "sentence": "Although relevant and usable for new players in the field, it does not yet provide the granularity needed to have a prioritized view of activities within the cycle.",
            "startOffset": 42346,
            "title": "Introduction"
        },
        {
            "endOffset": 68569,
            "parents": [],
            "secId": "s0065",
            "sentence": "The execution of stage-gates, the timing of parallel running workstreams, and the rigidity with which criteria are applied are dependent on contextual heterogeneities.",
            "startOffset": 68402,
            "title": "Discussion"
        },
        {
            "endOffset": 69135,
            "parents": [],
            "refoffsets": {
                "b0070": {
                    "endOffset": 69134,
                    "startOffset": 69127
                },
                "b0125": {
                    "endOffset": 69134,
                    "startOffset": 69127
                }
            },
            "secId": "s0065",
            "sentence": "This may result in unnecessary delays since late-stage preclinical studies may need to be reiterated contingent on changes in the production process [14,25].",
            "startOffset": 68978,
            "title": "Discussion"
        },
        {
            "endOffset": 44516,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "refoffsets": {
                "b0215": {
                    "endOffset": 44515,
                    "startOffset": 44511
                }
            },
            "secId": "s0015",
            "sentence": "Consisting of a set of predefined evaluation criteria, these gates enable fact-based decision-making that is likely to improve project effectiveness and efficiency [43].",
            "startOffset": 44347,
            "title": "Conceptual framework"
        },
        {
            "endOffset": 56995,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Results"
                },
                {
                    "id": "s0040",
                    "title": "Description of stages and gates"
                }
            ],
            "secId": "s0050",
            "sentence": "Moreover, the undefined stages and gates do not occur in a fixed order.",
            "startOffset": 56924,
            "title": "Stages and gates at undefined loci"
        },
        {
            "endOffset": 55499,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Results"
                },
                {
                    "id": "s0040",
                    "title": "Description of stages and gates"
                }
            ],
            "secId": "s0045",
            "sentence": "Nevertheless, iterations of activities within the same group occur, which may result in stages within one group running in parallel as well (e.g. after completion of RCT Phase II, an RCT Phase III and an RCT Phase II are started).",
            "startOffset": 55269,
            "title": "Stages and gates at defined loci"
        },
        {
            "endOffset": 58653,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Results"
                },
                {
                    "id": "s0040",
                    "title": "Description of stages and gates"
                }
            ],
            "secId": "s0055",
            "sentence": "A general alignment of the monitoring stages and gates with the defined and undefined stage-gates is presented in Fig. 5.",
            "startOffset": 58532,
            "title": "Monitoring stages and gates"
        },
        {
            "endOffset": 67909,
            "parents": [],
            "refoffsets": {
                "b0310": {
                    "endOffset": 67908,
                    "startOffset": 67904
                }
            },
            "secId": "s0065",
            "sentence": "In contrast, market feasibility is a step-limiting factor for vaccines in developing countries, as elaborated on for disease-specific, not-for-profit product development partnerships [62].",
            "startOffset": 67721,
            "title": "Discussion"
        },
        {
            "endOffset": 65255,
            "parents": [],
            "secId": "s0065",
            "sentence": "Innovations may originate from a clinical setting, industrial process optimization may contribute to fundamental knowledge creation and through transdisciplinary research, scientists and clinicians can simultaneously develop and implement knowledge.",
            "startOffset": 65006,
            "title": "Discussion"
        },
        {
            "endOffset": 70169,
            "parents": [],
            "secId": "s0070",
            "sentence": "Such a boundary-spanning function may contribute to reducing innovation process inefficiencies and additionally inform stakeholders about product development timelines, costs and risks, thereby helping with better prioritization and allocation of resources.",
            "startOffset": 69912,
            "title": "Conclusion"
        },
        {
            "endOffset": 61352,
            "parents": [],
            "secId": "s0065",
            "sentence": "Additionally, it conceptualizes the difference between incremental and radical vaccine innovation.",
            "startOffset": 61254,
            "title": "Discussion"
        },
        {
            "endOffset": 52219,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0030",
            "sentence": "Based on the comments regarding the comprehensibility of the model, changes to the layout were made and a revised model was drawn-up.",
            "startOffset": 52086,
            "title": "Survey"
        },
        {
            "endOffset": 49072,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0025",
            "sentence": "A short description of stage-related activities and deliverables were grouped next to gate-related criteria and outcomes in tables.",
            "startOffset": 48941,
            "title": "Interviews"
        },
        {
            "endOffset": 51339,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "refoffsets": {
                "b0245": {
                    "endOffset": 51338,
                    "startOffset": 51334
                }
            },
            "secId": "s0030",
            "sentence": "After receiving an initial invitation, all KOLs received one general reminder and one final reminder to increase response rates [49].",
            "startOffset": 51206,
            "title": "Survey"
        },
        {
            "endOffset": 54378,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Results"
                },
                {
                    "id": "s0040",
                    "title": "Description of stages and gates"
                }
            ],
            "secId": "s0045",
            "sentence": "A description of each of these stages and gates is provided in Table 1.",
            "startOffset": 54307,
            "title": "Stages and gates at defined loci"
        },
        {
            "endOffset": 39321,
            "parents": [],
            "refoffsets": {
                "b0060": {
                    "endOffset": 39320,
                    "startOffset": 39316
                }
            },
            "secId": "s0005",
            "sentence": "Such collaborations, however, are not easy to establish and a range of challenges are present in these stakeholder collaborations [12].",
            "startOffset": 39186,
            "title": "Introduction"
        },
        {
            "endOffset": 68402,
            "parents": [],
            "secId": "s0065",
            "sentence": "In line with these findings, the KOLs in the current study commented that the influence of political and financial factors depends on the visibility, perception and urgency of the disease in question.",
            "startOffset": 68202,
            "title": "Discussion"
        },
        {
            "endOffset": 57445,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Results"
                },
                {
                    "id": "s0040",
                    "title": "Description of stages and gates"
                }
            ],
            "secId": "s0050",
            "sentence": "Manufacturing (S22) is an undefined gate because its timing is contingent on development and market conditions that result in changes in demand.",
            "startOffset": 57301,
            "title": "Stages and gates at undefined loci"
        },
        {
            "endOffset": 59417,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "Importantly, although some criteria are only applied at one gate, they can still abort successful innovation.",
            "startOffset": 59308,
            "title": "Gate criteria"
        },
        {
            "endOffset": 37551,
            "parents": [],
            "refoffsets": {
                "b0110": {
                    "endOffset": 37550,
                    "startOffset": 37543
                },
                "b0115": {
                    "endOffset": 37550,
                    "startOffset": 37543
                }
            },
            "secId": "s0005",
            "sentence": "Moreover, they struggle with a limited viability, resulting in a lack of affordable, available and accessible vaccines that address societal unmet needs [22,23].",
            "startOffset": 37390,
            "title": "Introduction"
        },
        {
            "endOffset": 39070,
            "parents": [],
            "refoffsets": {
                "b0100": {
                    "endOffset": 39069,
                    "startOffset": 39056
                },
                "b0105": {
                    "endOffset": 39069,
                    "startOffset": 39056
                },
                "b0130": {
                    "endOffset": 39069,
                    "startOffset": 39056
                },
                "b0135": {
                    "endOffset": 39069,
                    "startOffset": 39056
                },
                "b0140": {
                    "endOffset": 39069,
                    "startOffset": 39056
                }
            },
            "secId": "s0005",
            "sentence": "To address the innovation paradox and develop radical innovations into novel vaccines, improved collaboration between stakeholders from different disciplines and across different sectors is therefore essential [20,21,26\u201328].",
            "startOffset": 38846,
            "title": "Introduction"
        },
        {
            "endOffset": 43374,
            "parents": [],
            "secId": "s0005",
            "sentence": "Therefore, in order to improve resource allocation and innovation effectiveness, here we provide granularity to the VTTC in terms of activities and criteria as prioritized by Key Opinion Leaders (KOLs) in vaccine innovation.",
            "startOffset": 43150,
            "title": "Introduction"
        },
        {
            "endOffset": 39185,
            "parents": [],
            "refoffsets": {
                "b0105": {
                    "endOffset": 39184,
                    "startOffset": 39177
                },
                "b0145": {
                    "endOffset": 39184,
                    "startOffset": 39177
                }
            },
            "secId": "s0005",
            "sentence": "Accordingly, efforts have been made towards co-development of vaccines through public-private partnerships [21,29].",
            "startOffset": 39070,
            "title": "Introduction"
        },
        {
            "endOffset": 42658,
            "parents": [],
            "secId": "s0005",
            "sentence": "In addition, this model does not provide context on the criteria used to evaluate whether each stage of activities has been successfully completed.",
            "startOffset": 42511,
            "title": "Introduction"
        },
        {
            "endOffset": 51206,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0030",
            "sentence": "A pilot study with four respondents was conducted to ensure that all questions were clear and to verify how much time on average it would take to fill out the questionnaire.",
            "startOffset": 51033,
            "title": "Survey"
        },
        {
            "endOffset": 56802,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Results"
                },
                {
                    "id": "s0040",
                    "title": "Description of stages and gates"
                }
            ],
            "secId": "s0050",
            "sentence": "A description of each of these stages and gates is provided in Table 2.",
            "startOffset": 56731,
            "title": "Stages and gates at undefined loci"
        },
        {
            "endOffset": 47338,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0025",
            "sentence": "Interviews were conducted via telephone and started with an explicit, oral informed consent on data collection for the purpose of this study, with respondents being anonymized and transcripts not being made publicly available to prevent de-anomyization.",
            "startOffset": 47085,
            "title": "Interviews"
        },
        {
            "endOffset": 59100,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "External criteria, confined to fixed evaluation points by competent authorities, are used to assess whether vaccine candidates have adequately addressed the requirements for continuation into the next stage.",
            "startOffset": 58893,
            "title": "Gate criteria"
        },
        {
            "endOffset": 51431,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0030",
            "sentence": "The first invitation was sent in September 2017 and the survey was closed in November 2017.",
            "startOffset": 51340,
            "title": "Survey"
        },
        {
            "endOffset": 60345,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "A detailed overview of the internal criteria per gate are shown in Supplementary Material 4 (defined gates), Supplementary Material 5 (monitoring gates) and Supplementary Material 6 (undefined gates).",
            "startOffset": 60145,
            "title": "Gate criteria"
        },
        {
            "endOffset": 41917,
            "parents": [],
            "refoffsets": {
                "b0205": {
                    "endOffset": 41916,
                    "startOffset": 41912
                }
            },
            "secId": "s0005",
            "sentence": "In the context of the Nagoya Protocol to the Convention on Biological Diversity, these domains have become even more important, as recently shown for the sharing of isolates and data from microorganisms [41].",
            "startOffset": 41709,
            "title": "Introduction"
        },
        {
            "endOffset": 63700,
            "parents": [],
            "refoffsets": {
                "b0140": {
                    "endOffset": 63699,
                    "startOffset": 63695
                }
            },
            "secId": "s0065",
            "sentence": "In contrast, a thorough understanding and concordance of unmet needs can align actors involved in innovation and accelerate responses to (emerging) infectious diseases [28].",
            "startOffset": 63527,
            "title": "Discussion"
        },
        {
            "endOffset": 55268,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Results"
                },
                {
                    "id": "s0040",
                    "title": "Description of stages and gates"
                }
            ],
            "secId": "s0045",
            "sentence": "The general order and alignment of the stage-gates is presented in Fig. 3.",
            "startOffset": 55194,
            "title": "Stages and gates at defined loci"
        },
        {
            "endOffset": 54901,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Results"
                },
                {
                    "id": "s0040",
                    "title": "Description of stages and gates"
                }
            ],
            "secId": "s0045",
            "sentence": "In addition, the start of some activities within one group is contingent upon successful completion of activities within another group.",
            "startOffset": 54766,
            "title": "Stages and gates at defined loci"
        },
        {
            "endOffset": 50243,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0030",
            "sentence": "After gathering respondent\u2019s demographic data, the draft model was introduced and general responses regarding the understandability of the model were collected.",
            "startOffset": 50083,
            "title": "Survey"
        },
        {
            "endOffset": 44346,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0015",
            "sentence": "SG is based on the premise that often economically risky and technically uncertain R&D projects benefit from managing that risk through structured evaluation moments; so-called gates.",
            "startOffset": 44163,
            "title": "Conceptual framework"
        },
        {
            "endOffset": 61562,
            "parents": [],
            "secId": "s0065",
            "sentence": "By highlighting the gap between internal criteria used to evaluate the progress of vaccine candidates and external criteria applied by competent authorities, newcomers to the field can enhance their viability.",
            "startOffset": 61353,
            "title": "Discussion"
        },
        {
            "endOffset": 56425,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Results"
                },
                {
                    "id": "s0040",
                    "title": "Description of stages and gates"
                }
            ],
            "secId": "s0050",
            "sentence": "The first group relates to activities necessary for the business development of the innovation; and includes funding, IP protection, and strategic partnership.",
            "startOffset": 56266,
            "title": "Stages and gates at undefined loci"
        },
        {
            "endOffset": 43503,
            "parents": [],
            "secId": "s0010",
            "sentence": "Building upon the stage-gate model as a conceptual framework, the methodology for this study consisted of two phases.",
            "startOffset": 43386,
            "title": "Methodology"
        },
        {
            "endOffset": 47396,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0025",
            "sentence": "The semi-structured interviews were based on a topic list.",
            "startOffset": 47338,
            "title": "Interviews"
        },
        {
            "endOffset": 57523,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Results"
                },
                {
                    "id": "s0040",
                    "title": "Description of stages and gates"
                }
            ],
            "secId": "s0050",
            "sentence": "Moreover, activities such as quality inspection occur at unannounced moments.",
            "startOffset": 57446,
            "title": "Stages and gates at undefined loci"
        },
        {
            "endOffset": 59851,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "The majority of internal criteria apply to all three types of gates, as shown in Table 4.",
            "startOffset": 59762,
            "title": "Gate criteria"
        },
        {
            "endOffset": 56923,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Results"
                },
                {
                    "id": "s0040",
                    "title": "Description of stages and gates"
                }
            ],
            "secId": "s0050",
            "sentence": "Unlike defined stages and gates, the fulfillment of all undefined stage-gates is not required for each vaccine candidate.",
            "startOffset": 56802,
            "title": "Stages and gates at undefined loci"
        },
        {
            "endOffset": 60144,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "Additionally, while progressing through the value chain the criteria are more strictly applied.",
            "startOffset": 60049,
            "title": "Gate criteria"
        },
        {
            "endOffset": 46699,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0020",
            "sentence": "18 out of 40 invited KOLs agreed to participate in the interviews (response rate = 45%).",
            "startOffset": 46611,
            "title": "Interview respondents"
        },
        {
            "endOffset": 62305,
            "parents": [],
            "secId": "s0065",
            "sentence": "The current study therefore adds to the existing body of knowledge by extending the description of vaccine innovation to include less defined processes such as funding and business development, post-marketing surveillance, and other monitoring processes.",
            "startOffset": 62051,
            "title": "Discussion"
        },
        {
            "endOffset": 43673,
            "parents": [],
            "secId": "s0010",
            "sentence": "In the first phase, 18 qualitative interviews were held with key opinion leaders (KOLs) in the field to identify stages and gates within the vaccine development process.",
            "startOffset": 43504,
            "title": "Methodology"
        },
        {
            "endOffset": 60730,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "These criteria ensure the long-term viability of the stakeholders who develop the vaccine candidates.",
            "startOffset": 60629,
            "title": "Gate criteria"
        },
        {
            "endOffset": 41708,
            "parents": [],
            "secId": "s0005",
            "sentence": "Both models do not elucidate the role that stakeholders from market and societal domains play in vaccine innovation.",
            "startOffset": 41592,
            "title": "Introduction"
        },
        {
            "endOffset": 51802,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0030",
            "sentence": "The demographic characteristics of the respondents of the survey are shown in Supplementary File 2.",
            "startOffset": 51703,
            "title": "Survey"
        },
        {
            "endOffset": 56660,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Results"
                },
                {
                    "id": "s0040",
                    "title": "Description of stages and gates"
                }
            ],
            "secId": "s0050",
            "sentence": "In contrast to the grouping of defined stage-gates, stages within this group do not necessarily occur sequentially, but they all contribute to the commercial viability of the organization active in research and development activities.",
            "startOffset": 56426,
            "title": "Stages and gates at undefined loci"
        },
        {
            "endOffset": 52521,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0030",
            "sentence": "The finally identified criteria were analysed for their use by different stakeholders; either by stakeholders directly contributing to vaccine innovation (internal criteria), or by stakeholders evaluating whether progress meets predetermined guidelines set by competent authorities (external criteria).",
            "startOffset": 52219,
            "title": "Survey"
        },
        {
            "endOffset": 56730,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Results"
                },
                {
                    "id": "s0040",
                    "title": "Description of stages and gates"
                }
            ],
            "secId": "s0050",
            "sentence": "The second group consists of one stage-gate related to manufacturing.",
            "startOffset": 56661,
            "title": "Stages and gates at undefined loci"
        },
        {
            "endOffset": 68977,
            "parents": [],
            "secId": "s0065",
            "sentence": "In industry, the CMC stage is generally completed before late-stage preclinical studies are started, whereas academic organizations often continue into late-stage preclinical studies before ascertaining the feasibility of large-scale production under GMP conditions.",
            "startOffset": 68711,
            "title": "Discussion"
        },
        {
            "endOffset": 37753,
            "parents": [],
            "secId": "s0005",
            "sentence": "This is irrespective of the importance of SMEs for radical innovations such as vaccines that build upon scientific advances or use novel marketing approaches to deliver new product-market combinations.",
            "startOffset": 37552,
            "title": "Introduction"
        },
        {
            "endOffset": 38845,
            "parents": [],
            "refoffsets": {
                "b0125": {
                    "endOffset": 38844,
                    "startOffset": 38840
                }
            },
            "secId": "s0005",
            "sentence": "For that, a need for international collaboration, engagement and communication between regulators and those using or recommending vaccines is needed [25].",
            "startOffset": 38691,
            "title": "Introduction"
        },
        {
            "endOffset": 55193,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Results"
                },
                {
                    "id": "s0040",
                    "title": "Description of stages and gates"
                }
            ],
            "secId": "s0045",
            "sentence": "Successful completion of Phase III clinical trials is needed before market registration can be started.",
            "startOffset": 55090,
            "title": "Stages and gates at defined loci"
        },
        {
            "endOffset": 66426,
            "parents": [],
            "secId": "s0065",
            "sentence": "By investigating and explicating the internal and external criteria that are used in different stages of vaccine innovation, the current study contributes to improved stakeholder understanding of the constraints and requirements for vaccine innovation.",
            "startOffset": 66174,
            "title": "Discussion"
        },
        {
            "endOffset": 37001,
            "parents": [],
            "refoffsets": {
                "b0085": {
                    "endOffset": 37000,
                    "startOffset": 36996
                }
            },
            "secId": "s0005",
            "sentence": "The commercialization process of new medical entities is like \u201ctrying to thread a long string through 10.000 sequential needles\u201d, while missing any checkpoint could mean the development of the entity is doomed [17].",
            "startOffset": 36786,
            "title": "Introduction"
        },
        {
            "endOffset": 48342,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0025",
            "sentence": "Interviews were conducted until saturation of stage-related activities and gate-related criteria was achieved, as evidenced by three subsequent interviews in which no new concepts were mentioned (see Fig. 2).",
            "startOffset": 48134,
            "title": "Interviews"
        },
        {
            "endOffset": 58404,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Results"
                },
                {
                    "id": "s0040",
                    "title": "Description of stages and gates"
                }
            ],
            "secId": "s0055",
            "sentence": "In general, five groups of activities can be identified within the monitoring stages and gates: (1) market monitoring, (2) innovation project monitoring, (3) portfolio monitoring, (4) public affairs monitoring, and (5) product monitoring.",
            "startOffset": 58166,
            "title": "Monitoring stages and gates"
        },
        {
            "endOffset": 49540,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0030",
            "sentence": "E-mail addresses from 209 KOLs were collected.",
            "startOffset": 49494,
            "title": "Survey"
        },
        {
            "endOffset": 63825,
            "parents": [],
            "secId": "s0065",
            "sentence": "The circular nature of the model additionally enables the conceptual distinction between incremental and radical innovations.",
            "startOffset": 63700,
            "title": "Discussion"
        },
        {
            "endOffset": 68032,
            "parents": [],
            "secId": "s0065",
            "sentence": "Differences in criteria between vaccines for developed and developing countries are also prominent in the societal domain.",
            "startOffset": 67910,
            "title": "Discussion"
        },
        {
            "endOffset": 38144,
            "parents": [],
            "refoffsets": {
                "b0130": {
                    "endOffset": 38143,
                    "startOffset": 38139
                }
            },
            "secId": "s0005",
            "sentence": "Still, SMEs usually develop vaccines for high-income markets due to the greater potential for return on investments, rather than focusing on products that are designed for use in low-income countries\u2019 immunization programs [26].",
            "startOffset": 37916,
            "title": "Introduction"
        },
        {
            "endOffset": 62948,
            "parents": [],
            "refoffsets": {
                "b0070": {
                    "endOffset": 62947,
                    "startOffset": 62943
                }
            },
            "secId": "s0065",
            "sentence": "Such parallel processing is a necessary approach to reduce delays to authorization, especially in the context of public health emergencies [14].",
            "startOffset": 62804,
            "title": "Discussion"
        },
        {
            "endOffset": 64561,
            "parents": [],
            "refoffsets": {
                "b0150": {
                    "endOffset": 64560,
                    "startOffset": 64556
                }
            },
            "secId": "s0065",
            "sentence": "All these incremental innovations can be conceptualized as new iterations of the vaccine innovation cycle for the same product-market combination in which at least a number of stages are informed by successful completion of the VIC by previous vaccine products [30].",
            "startOffset": 64295,
            "title": "Discussion"
        },
        {
            "endOffset": 36040,
            "parents": [],
            "refoffsets": {
                "b0005": {
                    "endOffset": 36039,
                    "startOffset": 36034
                },
                "b0010": {
                    "endOffset": 36039,
                    "startOffset": 36034
                },
                "b0015": {
                    "endOffset": 36039,
                    "startOffset": 36034
                },
                "b0020": {
                    "endOffset": 36039,
                    "startOffset": 36034
                },
                "b0025": {
                    "endOffset": 36039,
                    "startOffset": 36034
                },
                "b0030": {
                    "endOffset": 36039,
                    "startOffset": 36034
                }
            },
            "secId": "s0005",
            "sentence": "Vaccines are considered one of the greatest achievements in medicine, since they are a cost-effective strategy to decrease the global burden of infectious diseases [1\u20136].",
            "startOffset": 35870,
            "title": "Introduction"
        },
        {
            "endOffset": 62803,
            "parents": [],
            "secId": "s0065",
            "sentence": "Moreover, the VIC depicts how these sub processes are executed in parallel in order to reduce development timelines.",
            "startOffset": 62687,
            "title": "Discussion"
        },
        {
            "endOffset": 40289,
            "parents": [],
            "refoffsets": {
                "b0175": {
                    "endOffset": 40288,
                    "startOffset": 40281
                },
                "b0180": {
                    "endOffset": 40288,
                    "startOffset": 40281
                },
                "b0185": {
                    "endOffset": 40288,
                    "startOffset": 40281
                }
            },
            "secId": "s0005",
            "sentence": "Finally, stakeholders from different domains have diverging norms and priorities, complicating cross-domain collaborations [35\u201337].",
            "startOffset": 40158,
            "title": "Introduction"
        },
        {
            "endOffset": 42817,
            "parents": [],
            "refoffsets": {
                "b0160": {
                    "endOffset": 42816,
                    "startOffset": 42812
                }
            },
            "secId": "s0005",
            "sentence": "Insight into the processes, activities and criteria employed in each domain can foster mutual understanding and enhance recognition of each other\u2019s work [32].",
            "startOffset": 42659,
            "title": "Introduction"
        },
        {
            "endOffset": 54306,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Results"
                },
                {
                    "id": "s0040",
                    "title": "Description of stages and gates"
                }
            ],
            "secId": "s0045",
            "sentence": "Some stages may run in parallel or iteratively, but the gates directly follow the stages and often successful completion of a certain gate is necessary before a subsequent stage can be started.",
            "startOffset": 54113,
            "title": "Stages and gates at defined loci"
        },
        {
            "endOffset": 46468,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0020",
            "sentence": "Potential interviewees were considered eligible if their backgrounds clearly demonstrated expertise with the subject matter.",
            "startOffset": 46344,
            "title": "Interview respondents"
        },
        {
            "endOffset": 48133,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0025",
            "sentence": "Respondents were asked to comment on the activities taking place, the deliverables of each stage, the evaluation criteria, the results and outcomes and the actors involved.",
            "startOffset": 47961,
            "title": "Interviews"
        },
        {
            "endOffset": 45666,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0020",
            "sentence": "KOLs, characterised as influential individuals within vaccine innovation, were considered the most appropriate informants for constructing a conceptual process model for their specific field.",
            "startOffset": 45475,
            "title": "Interview respondents"
        },
        {
            "endOffset": 51574,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "refoffsets": {
                "b0250": {
                    "endOffset": 51573,
                    "startOffset": 51569
                }
            },
            "secId": "s0030",
            "sentence": "At that moment, 64 responses had been collected, indicating a response rate of 31%, which is well within the norm for surveys (36 \u00b1 13%) [50].",
            "startOffset": 51432,
            "title": "Survey"
        },
        {
            "endOffset": 53332,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Results"
                }
            ],
            "secId": "s0040",
            "sentence": "Respondents from both interviews and survey indicated that some stages were part of a clear value chain and occurred in a fixed order.",
            "startOffset": 53198,
            "title": "Description of stages and gates"
        },
        {
            "endOffset": 47960,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "refoffsets": {
                "b0210": {
                    "endOffset": 47872,
                    "startOffset": 47868
                }
            },
            "secId": "s0025",
            "sentence": "For the first interviews these were derived from a previous version of the VTTC [42], and for each subsequent interview findings from previous interviews were incorporated.",
            "startOffset": 47788,
            "title": "Interviews"
        },
        {
            "endOffset": 60628,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "Six internal criteria are unmatched with external criteria.",
            "startOffset": 60569,
            "title": "Gate criteria"
        },
        {
            "endOffset": 65959,
            "parents": [],
            "secId": "s0065",
            "sentence": "As mentioned by one of the respondents from the survey: \u201c[Where you start] all depends from whose stakeholder perspective you look at the innovation cycle - as an innovator, national policy maker, manufacturer, donor, investor etc.\u201d Additionally, it is important to point out that many elements depicted at the stage level are in essence non-linear as well.",
            "startOffset": 65602,
            "title": "Discussion"
        },
        {
            "endOffset": 66915,
            "parents": [],
            "refoffsets": {
                "b0105": {
                    "endOffset": 66914,
                    "startOffset": 66910
                }
            },
            "secId": "s0065",
            "sentence": "This is especially relevant for SMEs who struggle to acquire the relevant expertise and funding to bring vaccine candidates closer to market deployment [21].",
            "startOffset": 66758,
            "title": "Discussion"
        },
        {
            "endOffset": 67269,
            "parents": [],
            "secId": "s0065",
            "sentence": "Interestingly, market feasibility was not mentioned as a criterion in later stage-gates within R&D processes.",
            "startOffset": 67160,
            "title": "Discussion"
        },
        {
            "endOffset": 50082,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0030",
            "sentence": "The cross-sectional survey was developed in SurveyMonkey and started with an informed consent, a notice of confidentiality, and a time indication.",
            "startOffset": 49936,
            "title": "Survey"
        },
        {
            "endOffset": 51032,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "refoffsets": {
                "b0240": {
                    "endOffset": 51031,
                    "startOffset": 51027
                }
            },
            "secId": "s0030",
            "sentence": "For that group, respondents were asked to reflect on the semantic quality of the model (e.g. whether the information provided was correct, complete, relevant and sufficiently reflecting the course of actions in the real-world) and on the comprehensibility of the model (e.g. whether the model provided insights on the activities within their domain and met informational needs) [48].",
            "startOffset": 50649,
            "title": "Survey"
        },
        {
            "endOffset": 64765,
            "parents": [],
            "secId": "s0065",
            "sentence": "The cyclical nature thus also takes into account the comfortable position of existing players that build upon previous iterations of the VIC and the market introgression difficulties that newcomers face.",
            "startOffset": 64562,
            "title": "Discussion"
        },
        {
            "endOffset": 49382,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0025",
            "sentence": "Stage-gates that occurred in a sequential manner were placed on one line, stage-gates that occurred in a parallel manner were grouped on different lines.",
            "startOffset": 49229,
            "title": "Interviews"
        },
        {
            "endOffset": 54112,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Results"
                },
                {
                    "id": "s0040",
                    "title": "Description of stages and gates"
                }
            ],
            "secId": "s0045",
            "sentence": "These stage-gates occur in a relatively predictive order and timing.",
            "startOffset": 54044,
            "title": "Stages and gates at defined loci"
        },
        {
            "endOffset": 64933,
            "parents": [],
            "secId": "s0065",
            "sentence": "In contrast to incremental innovations, radical innovations create novel product-market combinations and innovators can determine their own starting point in the cycle.",
            "startOffset": 64765,
            "title": "Discussion"
        },
        {
            "endOffset": 60474,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "A gap-overlap analysis showed that almost half of the internal criteria are directly aligned with external criteria (see Fig. 6).",
            "startOffset": 60345,
            "title": "Gate criteria"
        },
        {
            "endOffset": 65601,
            "parents": [],
            "secId": "s0065",
            "sentence": "The lack of a clear starting point facilitates interpretation of the model from different stakeholder perspectives.",
            "startOffset": 65486,
            "title": "Discussion"
        },
        {
            "endOffset": 44162,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "refoffsets": {
                "b0215": {
                    "endOffset": 44161,
                    "startOffset": 44154
                },
                "b0220": {
                    "endOffset": 44161,
                    "startOffset": 44154
                }
            },
            "secId": "s0015",
            "sentence": "has become a widely implemented managerial tool for guiding new product projects from initial idea to market launch and beyond [43,44].",
            "startOffset": 44027,
            "title": "Conceptual framework"
        },
        {
            "endOffset": 60048,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "Throughout the value chain, the sub-criteria per criteria may evolve.",
            "startOffset": 59979,
            "title": "Gate criteria"
        },
        {
            "endOffset": 64149,
            "parents": [],
            "refoffsets": {
                "b0150": {
                    "endOffset": 64148,
                    "startOffset": 64144
                },
                "b0270": {
                    "endOffset": 64073,
                    "startOffset": 64066
                },
                "b0295": {
                    "endOffset": 64073,
                    "startOffset": 64066
                }
            },
            "secId": "s0065",
            "sentence": "Examples of such incremental innovations include the generation of influenza vaccines against novel strains [54,59], and changes to the intended use or manufacturing process of existing [30].",
            "startOffset": 63958,
            "title": "Discussion"
        },
        {
            "endOffset": 48941,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0025",
            "sentence": "Finally, this led to the identification of 20 stages and 26 gates.",
            "startOffset": 48875,
            "title": "Interviews"
        },
        {
            "endOffset": 63194,
            "parents": [],
            "refoffsets": {
                "b0045": {
                    "endOffset": 63193,
                    "startOffset": 63190
                }
            },
            "secId": "s0065",
            "sentence": "The cyclical nature of the model clarifies that research can be executed through technology push (with a starting point in the exploration & discovery domain) or through market pull (via synchronisation of research with unmet societal needs) [9].",
            "startOffset": 62948,
            "title": "Discussion"
        },
        {
            "endOffset": 50648,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0030",
            "sentence": "Subsequently, they were asked to choose a group of activities within that domain (e.g. \u201cScoping, exploration and pre-clinical\u201d or \u201cCMC\u201d for the science domain; or \u201cPreparation and actual manufacturing\u201d or \u201cPreclinical, clinical and market preparation\u201d for the business development domain).",
            "startOffset": 50359,
            "title": "Survey"
        },
        {
            "endOffset": 36785,
            "parents": [],
            "refoffsets": {
                "b0050": {
                    "endOffset": 36625,
                    "startOffset": 36621
                },
                "b0055": {
                    "endOffset": 36658,
                    "startOffset": 36654
                },
                "b0060": {
                    "endOffset": 36700,
                    "startOffset": 36693
                },
                "b0065": {
                    "endOffset": 36700,
                    "startOffset": 36693
                },
                "b0070": {
                    "endOffset": 36731,
                    "startOffset": 36727
                },
                "b0075": {
                    "endOffset": 36784,
                    "startOffset": 36777
                },
                "b0080": {
                    "endOffset": 36784,
                    "startOffset": 36777
                }
            },
            "secId": "s0005",
            "sentence": "Vaccine innovation requires the inclusion of a wide variety of expertise, including societal demand articulation [10], basic and applied research [11], intellectual property management [12,13], market and manufacturing [14], quality assurance and regulatory compliance [15,16].",
            "startOffset": 36508,
            "title": "Introduction"
        },
        {
            "endOffset": 57301,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Results"
                },
                {
                    "id": "s0040",
                    "title": "Description of stages and gates"
                }
            ],
            "secId": "s0050",
            "sentence": "Although the exact timing of these stage-gates cannot be defined beforehand and some stages (e.g. funding, IP protection or partnering) occur multiple times throughout a vaccine innovation project, a general order of these stage-gates and the alignment with the defined stage-gates is presented in Fig. 4.",
            "startOffset": 56996,
            "title": "Stages and gates at undefined loci"
        },
        {
            "endOffset": 59978,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "The most prominent evaluation criteria are commercial feasibility, technical feasibility, strategic fit and budget feasibility.",
            "startOffset": 59851,
            "title": "Gate criteria"
        },
        {
            "endOffset": 44026,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0015",
            "sentence": "Based on studies of R&D processes within major corporations, the Stage-Gate (SG) system by Robert Cooper cs.",
            "startOffset": 43918,
            "title": "Conceptual framework"
        },
        {
            "endOffset": 48417,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0025",
            "sentence": "Interviews were audio recorded and manually transcribed by the interviewer.",
            "startOffset": 48342,
            "title": "Interviews"
        },
        {
            "endOffset": 49228,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0025",
            "sentence": "The stages with their activities and the gates with their criteria were combined into a first graphical draft of the model, consisting of concentric lines.",
            "startOffset": 49073,
            "title": "Interviews"
        },
        {
            "endOffset": 52085,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0030",
            "sentence": "Based on the comments on the semantic quality and comprehensibility of the model, the stage-related activities and gate-related criteria were reformulated, and some items were divided into separate stages or gates.",
            "startOffset": 51871,
            "title": "Survey"
        },
        {
            "endOffset": 69505,
            "parents": [],
            "secId": "s0070",
            "sentence": "This study provides an overview of how different processes align and together contribute to successful vaccine innovation.",
            "startOffset": 69383,
            "title": "Conclusion"
        },
        {
            "endOffset": 62050,
            "parents": [],
            "refoffsets": {
                "b0270": {
                    "endOffset": 61981,
                    "startOffset": 61977
                },
                "b0275": {
                    "endOffset": 62016,
                    "startOffset": 62012
                },
                "b0280": {
                    "endOffset": 62049,
                    "startOffset": 62045
                }
            },
            "secId": "s0065",
            "sentence": "In addition, detailed descriptions exist for other technical steps within the VIC, including fundamental vaccine research [54], clinical vaccine development [55], and vaccination strategies [56].",
            "startOffset": 61855,
            "title": "Discussion"
        },
        {
            "endOffset": 67543,
            "parents": [],
            "refoffsets": {
                "b0305": {
                    "endOffset": 67542,
                    "startOffset": 67538
                }
            },
            "secId": "s0065",
            "sentence": "Moreover, the operationalization of market feasibility by the KOLs in our study was less inclusive than the definition used in the Total Systems Effectiveness framework that is currently being developed by the WHO to assist procurement stakeholders in decision-making [61].",
            "startOffset": 67270,
            "title": "Discussion"
        },
        {
            "endOffset": 40796,
            "parents": [],
            "refoffsets": {
                "b0105": {
                    "endOffset": 40795,
                    "startOffset": 40788
                },
                "b0170": {
                    "endOffset": 40795,
                    "startOffset": 40788
                }
            },
            "secId": "s0005",
            "sentence": "Models including cross-domain representations provide an overview of the whole vaccine innovation process and can thereby facilitate dialogue among stakeholders and contribute to a collective search for innovative solutions [21,34].",
            "startOffset": 40564,
            "title": "Introduction"
        },
        {
            "endOffset": 58893,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "In general, the criteria for the defined gates can be defined in two types.",
            "startOffset": 58818,
            "title": "Gate criteria"
        },
        {
            "endOffset": 38485,
            "parents": [],
            "refoffsets": {
                "b0100": {
                    "endOffset": 38484,
                    "startOffset": 38480
                }
            },
            "secId": "s0005",
            "sentence": "Furthermore, alignment of needs and strategies between vaccine developers, governments and NGOs is necessary to address changing societal and market unmet needs [20].",
            "startOffset": 38319,
            "title": "Introduction"
        },
        {
            "endOffset": 48776,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "refoffsets": {
                "b0235": {
                    "endOffset": 48775,
                    "startOffset": 48771
                }
            },
            "secId": "s0025",
            "sentence": "Data was subsequently analysed by two independent researchers using the conventional content analysis approach [47].",
            "startOffset": 48660,
            "title": "Interviews"
        },
        {
            "endOffset": 53526,
            "parents": [
                {
                    "id": "s0035",
                    "title": "Results"
                }
            ],
            "secId": "s0040",
            "sentence": "The occurrence and timing of other stage-gates was contingent on a wide variety of contextual factors, therefore being classified as \u201cundefined\u201d.",
            "startOffset": 53381,
            "title": "Description of stages and gates"
        },
        {
            "endOffset": 66174,
            "parents": [],
            "refoffsets": {
                "b0300": {
                    "endOffset": 66173,
                    "startOffset": 66169
                }
            },
            "secId": "s0065",
            "sentence": "These include activities that imply iteration, evaluation, and feedback and feed-forward (e.g. in exploration and discovery, CMC and market preparation), and demonstrate that innovation is non-linear at heart [60].",
            "startOffset": 65960,
            "title": "Discussion"
        },
        {
            "endOffset": 66991,
            "parents": [],
            "secId": "s0065",
            "sentence": "This description of internal criteria may improve reciprocal understanding.",
            "startOffset": 66916,
            "title": "Discussion"
        },
        {
            "endOffset": 51702,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methodology"
                }
            ],
            "secId": "s0030",
            "sentence": "From all respondents who started the survey, 46 completed questions on one of the domains, indicating a completion rate of 72%.",
            "startOffset": 51575,
            "title": "Survey"
        },
        {
            "endOffset": 67160,
            "parents": [],
            "refoffsets": {
                "b0290": {
                    "endOffset": 67159,
                    "startOffset": 67155
                }
            },
            "secId": "s0065",
            "sentence": "By acting upon this understanding to create win-win situations, stakeholders can improve their collaboration with other players, as previously described for Ebola [58].",
            "startOffset": 66992,
            "title": "Discussion"
        },
        {
            "endOffset": 66565,
            "parents": [],
            "secId": "s0065",
            "sentence": "Out of the five most prevalent criteria employed by vaccine innovators, only two are linked to criteria employed by competent authorities.",
            "startOffset": 66427,
            "title": "Discussion"
        },
        {
            "endOffset": 42345,
            "parents": [],
            "secId": "s0005",
            "sentence": "This model provides a more comprehensive understanding of the full range of domains involved in vaccine innovation and its cyclical nature allows for quality improvement based on existing expertise.",
            "startOffset": 42147,
            "title": "Introduction"
        }
    ],
    "docId": "S0264410X18314294",
    "metadata": {
        "asjc": [
            "1313",
            "2400",
            "2725",
            "2739",
            "3400"
        ],
        "authors": [
            {
                "email": "lvdburgwal@gmail.com",
                "first": "L. H.M.",
                "initial": "L.H.M.",
                "last": "Van de Burgwal"
            },
            {
                "email": null,
                "first": "C. Dos S.",
                "initial": "C.D.S.",
                "last": "Ribeiro"
            },
            {
                "email": null,
                "first": "M. B.",
                "initial": "M.B.",
                "last": "Van der Waal"
            },
            {
                "email": null,
                "first": "E.",
                "initial": "E.",
                "last": "Claassen"
            }
        ],
        "doi": "10.1016/j.vaccine.2018.10.061",
        "firstpage": "7496",
        "issn": "0264410X",
        "keywords": [
            "Conceptual model",
            "Efficiency",
            "Innovation",
            "Vaccine",
            "Valorization",
            "Value"
        ],
        "lastpage": "7508",
        "openaccess": "Full",
        "pub_year": 2018,
        "subjareas": [
            "BIOC",
            "IMMU",
            "MEDI",
            "VETE"
        ],
        "title": "Towards improved process efficiency in vaccine innovation: The Vaccine Innovation Cycle as a validated, conceptual stage-gate model"
    }
}